<PAGE> 1
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OF
THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED JANUARY 3, 1999 COMMISSION FILE NUMBER 1-3215
JOHNSON & JOHNSON
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<S> <C>
NEW JERSEY 22-1024240
(State of (I.R.S. Employer
Incorporation) Identification No.)
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NEW JERSEY 08933
(Address of principal executive offices) (Zip Code)
</TABLE>
Registrant's telephone number, including area code (732) 524-0400
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT
<TABLE>
<CAPTION>
TITLE OF EACH CLASS NAME OF EACH EXCHANGE ON WHICH REGISTERED
------------------- -----------------------------------------
<S> <C>
Common Stock, Par Value $1.00 New York Stock Exchange
</TABLE>
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K [ ]
The aggregate market value of the voting stock held by non-affiliates of
the registrant on February 23, 1999 was approximately $117.2 billion.
On February 23, 1999 there were 1,345,589,883 shares of Common Stock
outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
<TABLE>
<S> <C>
Parts I and Portions of registrant's annual report to shareowners for
II: fiscal year 1998.
Part III: Portions of registrant's proxy statement for its 1999 annual
meeting of shareowners.
</TABLE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE> 2
PART I
<TABLE>
<CAPTION>
ITEM PAGE
- ---- ----
<S> <C> <C>
1. Business.................................................... 1
General..................................................... 1
Segments of Business; Geographic Areas...................... 1
Consumer.................................................... 1
Pharmaceutical.............................................. 1
Professional................................................ 2
International............................................... 2
Raw Materials............................................... 2
Patents and Trademarks...................................... 2
Seasonality................................................. 3
Competition................................................. 3
Research.................................................... 3
Environment................................................. 3
Regulation.................................................. 3
2. Properties.................................................. 4
3. Legal Proceedings........................................... 4
4. Submission of Matters to a Vote of Security Holders......... 5
Executive Officers of the Registrant........................ 5
PART II
5. Market for the Registrant's Common Equity and Related
Shareowner Matters.......................................... 6
6. Selected Financial Data..................................... 6
7. Management's Discussion and Analysis of Financial Condition
and Results of Operations................................... 6
7A. Quantitative and Qualitative Disclosures About Market
Risk........................................................ 6
8. Financial Statements and Supplementary Data................. 6
9. Disagreements on Accounting and Financial Disclosure........ 6
PART III
10. Directors and Executive Officers of the Registrant.......... 7
11. Executive Compensation...................................... 7
12. Security Ownership of Certain Beneficial Owners and
Management.................................................. 7
13. Certain Relationships and Related Transactions.............. 7
PART IV
14. Exhibits, Financial Statement Schedules, and Reports on Form
8-K......................................................... 8
Signatures.................................................. 10
Report of Independent Auditors.............................. 12
Exhibit Index............................................... 13
</TABLE>
Form 10-Q Quarterly Reports Available. A copy of Johnson & Johnson's
Quarterly Report on Form 10-Q for any of the first three quarters of the current
fiscal year, without exhibits, will be provided without charge to any shareowner
submitting a written request to the Secretary at the principal executive offices
of the Company or by calling 800-328-9033. Each report will be available about
45 days after the end of the quarter to which it relates.
<PAGE> 3
PART I
ITEM 1. BUSINESS
GENERAL
Johnson & Johnson, employing approximately 93,100 people worldwide, is
engaged in the manufacture and sale of a broad range of products in the health
care field in many countries of the world. Johnson & Johnson's primary interest,
both historically and currently, has been in products related to health and
well-being. Johnson & Johnson was organized in the State of New Jersey in 1887.
Johnson & Johnson is organized on the principles of decentralized
management. The Executive Committee of Johnson & Johnson is the principal
management group responsible for the operations of Johnson & Johnson. In
addition, certain Executive Committee members serve as Worldwide Chairmen of
Group Operating Committees, which are comprised of managers who represent key
operations within the group, as well as management expertise in other
specialized functions. These Committees oversee and coordinate the activities of
domestic and international companies related to each of the Consumer,
Pharmaceutical and Professional segments of business. Operating management of
each company is headed by a Chairman, President, General Manager or Managing
Director who reports directly to, or through a line executive to, a Group
Operating Committee. In line with this policy of decentralization, each
international subsidiary is, with some exceptions, managed by citizens of the
country where it is located.
SEGMENTS OF BUSINESS; GEOGRAPHIC AREAS
Johnson & Johnson's worldwide business is divided into three segments:
Consumer, Pharmaceutical and Professional. Johnson & Johnson further categorizes
its sales and operating profit by major geographic areas of the world.
Additional information required by this item is incorporated herein by reference
to the narrative and tabular (but not the graphic) descriptions of segments and
geographic areas captioned "Management's Discussion and Analysis of Results of
Operations and Financial Condition -- Segments of Business, Consumer,
Pharmaceutical, Professional and Geographic Areas" on pages 27 through 30 and 45
of Johnson & Johnson's Annual Report to Shareowners for fiscal year 1998.
CONSUMER
The Consumer segment's principal products are personal care and hygienic
products, including oral and baby care products, first aid products,
nonprescription drugs, sanitary protection products and adult skin and hair care
products. Major brands include ACT Fluoride Rinse; BAND-AID Brand Adhesive
Bandages; CAREFREE Panty Shields; CLEAN & CLEAR Skin Care Products; IMODIUM A-D,
an antidiarrheal; JOHNSON'S Baby line of products; JOHNSON'S pH 5.5 skin and
hair care products; MONISTAT, a remedy for vaginal yeast infections; adult and
children's MOTRIN analgesic products; MYLANTA gastrointestinal products and
PEPCID AC Acid Controller from Johnson & Johnson - Merck Consumer
Pharmaceuticals Co.; NEUTROGENA skin and hair care products; NICOTROL smoking
cessation products; o.b. Tampons; PENATEN and NATUSAN baby care products; PIZ
BUIN and SUNDOWN sun care products; REACH toothbrushes; RoC skin care products;
SHOWER TO SHOWER personal care products; STAYFREE and SURE & NATURAL sanitary
protection products; and the broad family of TYLENOL acetaminophen products.
These products are marketed principally to the general public and distributed
both to wholesalers and directly to independent and chain retail outlets.
PHARMACEUTICAL
The Pharmaceutical segment's principal worldwide franchises are in the
allergy, anti-infective, antifungal, antianemia, central nervous system,
contraceptive, dermatology, gastrointestinal, and pain management fields. These
products are distributed both directly and through wholesalers for use by health
care professionals and the general public. Prescription drugs include DURAGESIC
(fentanyl transdermal system sold abroad as DUROGESIC), a transdermal patch for
chronic pain; EPREX (Epoetin alfa sold in the U.S. as PROCRIT), a biotechnology
derived version of the human hormone erythropoietin that stimulates red blood
cell
<PAGE> 4
production; ERGAMISOL (levamisole hydrochloride), a colon cancer drug; FLOXIN
(ofloxacin) and LEVAQUIN (levofloxacin), both anti-infectives; IMODIUM
(loperamide HCI), an antidiarrheal;
LEUSTATIN (cladribine), for hairy cell leukemia; MOTILIUM (domperidone), a
gastrointestinal mobilizer; NIZORAL (ketoconazole), SPORANOX (itraconazole) and
TERAZOL (terconazole), antifungals; ORTHOCLONE OKT-3 (muromonab-CD3), for
reversing the rejection of kidney, heart and liver transplants; ORTHO-NOVUM
(norethindrone/mestranol) group of oral contraceptives; PREPULSID (cisapride
sold in the U.S. as PROPULSID), a gastrointestinal prokinetic; RETIN-A
(tretinoin), a dermatological cream for acne; RISPERDAL (risperidone), an
antipsychotic drug; and ULTRAM (tramadol hydrochloride), a centrally acting
prescription analgesic for moderate to moderately severe pain.
PROFESSIONAL
The Professional segment includes suture and mechanical wound closure
products, minimally invasive surgical instruments, diagnostic products,
cardiology products, disposable contact lenses, surgical instruments,
orthopaedic joint replacements and products for wound management and infection
prevention and other medical equipment and devices. These products are used
principally in the professional fields by physicians, nurses, therapists,
hospitals, diagnostic laboratories and clinics. Distribution to these markets is
done both directly and through surgical supply and other dealers. In November
1998, Johnson & Johnson completed the acquisition of DePuy, Inc., an orthopaedic
products company with products in reconstructive, spinal, trauma and sports
medicine.
INTERNATIONAL
The international business of Johnson & Johnson is conducted by
subsidiaries manufacturing in 36 countries outside the United States and selling
in over 175 countries throughout the world. The products made and sold in the
international business include many of those described above under
"Business -- Consumer, Pharmaceutical and Professional." However, the principal
markets, products and methods of distribution in the international business vary
with the country and the culture. The products sold in the international
business include not only those which were developed in the United States but
also those which were developed by subsidiaries abroad.
Investments and activities in some countries outside the United States are
subject to higher risks than comparable domestic activities because the
investment and commercial climate is influenced by restrictive economic policies
and political uncertainties.
RAW MATERIALS
Raw materials essential to Johnson & Johnson's business are generally
readily available from multiple sources.
PATENTS AND TRADEMARKS
Johnson & Johnson has made a practice of obtaining patent protection on its
products and processes where possible. Johnson & Johnson owns or is licensed
under a number of patents relating to its products and manufacturing processes,
which in the aggregate are believed to be of material importance in the
operation of its business. However, it is believed that no single patent or
related group of patents is material in relation to Johnson & Johnson as a
whole.
Johnson & Johnson has made a practice of selling its products under
trademarks and of obtaining protection for these trademarks by all available
means. Johnson & Johnson's trademarks are protected by registration in the
United States and other countries where its products are marketed. Johnson &
Johnson considers these trademarks in the aggregate to be of material importance
in the operation of its business.
2
<PAGE> 5
SEASONALITY
Worldwide sales do not reflect any significant degree of seasonality;
however spending has been heavier in the fourth quarter of each year than in
other quarters. This reflects increased spending decisions, principally for
advertising and research grants.
COMPETITION
In all its product lines, Johnson & Johnson companies compete with
companies both large and small, located in the United States and abroad.
Competition is strong in all lines without regard to the number and size of the
competing companies involved. Competition in research, involving the development
of new products and processes and the improvement of existing products and
processes, is particularly significant and results from time to time in product
and process obsolescence. The development of new and improved products is
important to Johnson & Johnson's success in all areas of its business. This
competitive environment requires substantial investments in continuing research
and in multiple sales forces. In addition, the winning and retention of customer
acceptance of Johnson & Johnson's consumer products involve heavy expenditures
for advertising, promotion and selling.
RESEARCH
Research activities are important to all segments of Johnson & Johnson's
business. Major research facilities are located not only in the United States
but also in Australia, Belgium, Brazil, Canada, Germany, Switzerland and the
United Kingdom. The costs of Johnson & Johnson's worldwide research activities
relating to the development of new products, the improvement of existing
products, technical support of products and compliance with governmental
regulations for the protection of the consumer amounted to $2,269, $2,140 and
$1,905 million for fiscal years 1998, 1997 and 1996, respectively. These costs
are charged directly to income in the year in which incurred. All research was
sponsored by Johnson & Johnson.
ENVIRONMENT
During the past year Johnson & Johnson was subject to a variety of federal,
state and local environmental protection measures. Johnson & Johnson believes
that its operations comply in all material respects with applicable
environmental laws and regulations. Johnson & Johnson's compliance with these
requirements did not and is not expected to have a material effect upon its
capital expenditures, earnings or competitive position.
REGULATION
Most of Johnson & Johnson's business is subject to varying degrees of
governmental regulation in the countries in which operations are conducted, and
the general trend is toward regulation of increasing stringency. In the United
States, the drug, device, diagnostics and cosmetic industries have long been
subject to regulation by various federal, state and local agencies, primarily as
to product safety, efficacy, advertising and labeling. The exercise of broad
regulatory powers by the Food and Drug Administration (the "FDA") continues to
result in increases in the amounts of testing and documentation required for FDA
clearance of new drugs and devices and a corresponding increase in the expense
of product introduction. Similar trends toward product and process regulation
are also evident in a number of major countries outside of the United States,
especially in the European Economic Community where efforts are continuing to
harmonize the internal regulatory systems.
The costs of human health care have been and continue to be a subject of
study, investigation and regulation by governmental agencies and legislative
bodies in the United States and other countries. In the United States, attention
has been focused on drug prices and profits and programs that encourage doctors
to write prescriptions for particular drugs or recommend particular medical
devices. Even in the absence of new government regulation, managed care has
become a more potent force in the market place and it is likely that increased
attention will be paid to drug pricing, appropriate drug utilization and the
quality of health care.
3
<PAGE> 6
The regulatory agencies under whose purview Johnson & Johnson operates have
administrative powers that may subject Johnson & Johnson to such actions as
product recalls, seizure of products and other civil and criminal sanctions. In
some cases Johnson & Johnson may deem it advisable to initiate product recalls
voluntarily.
ITEM 2. PROPERTIES
Johnson & Johnson and its worldwide subsidiaries operate 175 manufacturing
facilities occupying approximately 17.8 million square feet of floor space.
The manufacturing facilities are used by the industry segments of Johnson &
Johnson's business approximately as follows:
<TABLE>
<CAPTION>
SQUARE FEET
SEGMENT (IN THOUSANDS)
------- --------------
<S> <C>
Consumer.................................................... 5,620
Pharmaceutical.............................................. 4,174
Professional................................................ 8,014
------
Worldwide total................................... 17,808
======
</TABLE>
Within the United States, 9 facilities are used by the Consumer segment, 9
by the Pharmaceutical segment and 51 by the Professional segment. Johnson &
Johnson's manufacturing operations outside the United States are often conducted
in facilities which serve more than one segment of the business.
The locations of the manufacturing facilities by major geographic areas of
the world are as follows:
<TABLE>
<CAPTION>
NUMBER
OF SQUARE FEET
GEOGRAPHIC AREA FACILITIES (IN THOUSANDS)
--------------- ---------- --------------
<S> <C> <C>
United States............................................... 69 7,999
Europe...................................................... 47 4,979
Western Hemisphere excluding U.S.A.......................... 20 2,483
Africa, Asia and Pacific.................................... 39 2,347
--- ------
Worldwide total................................... 175 17,808
=== ======
</TABLE>
In addition to the manufacturing facilities discussed above, Johnson &
Johnson maintains numerous office and warehouse facilities throughout the world.
Research facilities are also discussed in Item 1 under "Business -- Research."
Johnson & Johnson generally seeks to own its manufacturing facilities,
although some, principally in locations abroad, are leased. Office and warehouse
facilities are often leased.
Johnson & Johnson's properties are maintained in good operating condition
and repair and are well utilized.
For information regarding lease obligations see Note 9 "Rental Expense and
Lease Commitments" under "Notes to Consolidated Financial Statements" on page 38
of Johnson & Johnson's Annual Report to Shareowners for fiscal year 1998.
Segment information on additions to Johnson & Johnson's property, plant and
equipment is contained on page 45 of Johnson & Johnson's Annual Report to
Shareowners for fiscal year 1998. For information regarding plans to close
certain manufacturing facilities, see Note 15 "Restructuring and In-Process
Research and Development Charges" under "Notes to Consolidated Financial
Statements" on page 41 of Johnson & Johnson's Annual Report to Shareowners for
fiscal year 1998.
ITEM 3. LEGAL PROCEEDINGS
The information set forth in Note 18 "Pending Legal Proceedings" under
"Notes to Consolidated Financial Statements" on pages 42 through 43 of Johnson &
Johnson's Annual Report to Shareowners for fiscal year 1998 is incorporated
herein by reference.
4
<PAGE> 7
The Company or its subsidiaries are parties to a number of proceedings
brought under the Comprehensive Environmental Response, Compensation, and
Liability Act, commonly known as Superfund, and comparable state laws in which
the primary relief sought is the cost of past and future remediation. While it
is not feasible to predict or determine the outcome of these proceedings, in the
opinion of the Company, such proceedings would not have a material adverse
effect on the results of operations, cash flows or financial position of the
Company.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
Not applicable.
EXECUTIVE OFFICERS OF THE REGISTRANT
Listed below are the executive officers of Johnson & Johnson as of March
26, 1999, each of whom, unless otherwise indicated below, has been an employee
of the Company or its affiliates and held the position indicated during the past
five years. There are no family relationships between any of the executive
officers, and there is no arrangement or understanding between any executive
officer and any other person pursuant to which the executive officer was
selected. At the annual meeting of the Board of Directors which follows the
Annual Meeting of Shareowners executive officers are elected by the Board to
hold office for one year and until their respective successors are elected and
qualified, or until earlier resignation or removal.
Information with regard to the directors of the Company, including those of
the following executive officers who are directors, is incorporated herein by
reference to pages 3 through 6 of Johnson & Johnson's Proxy Statement dated
March 10, 1999.
<TABLE>
<CAPTION>
NAME AGE POSITION
---- --- --------
<S> <C> <C>
Robert J. Darretta..................... 52 Member, Executive Committee; Vice President,
Finance(a)
Russell C. Deyo........................ 49 Member, Executive Committee; Vice President,
Administration(b)
Roger S. Fine.......................... 56 Member, Executive Committee; Vice President, General
Counsel(c)
Ronald G. Gelbman...................... 51 Member, Executive Committee; Worldwide Chairman,
Health Systems and Diagnostics Group(d)
JoAnn Heffernan Heisen................. 49 Member, Executive Committee; Vice President, Chief
Information Officer(e)
Christian A. Koffmann.................. 58 Member, Executive Committee; Worldwide Chairman,
Consumer and Personal Care Group(f)
Ralph S. Larsen........................ 60 Chairman, Board of Directors and Chief Executive
Officer; Chairman, Executive Committee
James T. Lenehan....................... 50 Member, Executive Committee; Worldwide Chairman,
Consumer Pharmaceuticals and Professional Group(g)
William C. Weldon...................... 50 Member, Executive Committee; Worldwide Chairman,
Pharmaceuticals Group(h)
Robert N. Wilson....................... 58 Vice-Chairman, Board of Directors; Vice-Chairman
Executive Committee
</TABLE>
- ---------------
(a) Mr. R. J. Darretta joined the Company in 1968 and held various positions
before becoming President of Iolab Corporation in 1988 and Treasurer of the
Company in 1995. He became a Member of the Executive Committee and Vice
President, Finance in 1997.
(b) Mr. R. C. Deyo joined the Company in 1985 and became Associate General
Counsel in 1991. He became a Member of the Executive Committee and Vice
President, Administration in 1996.
(c) Mr. R. S. Fine joined the Company in 1974 and became Assistant General
Counsel in 1978 and Associate General Counsel in 1984. He became a Member of
the Executive Committee and Vice President, Administration in 1991 and
became Vice President, General Counsel in 1996.
(d) Mr. R. G. Gelbman joined the Company in 1972 and became a Company Group
Chairman in 1987 and a Member of the Executive Committee in 1994. He was
named Worldwide Chairman, Pharmaceutical and Diagnostics Group in 1994 and
Worldwide Chairman, Health Systems and Diagnostics Group in June 1998.
5
<PAGE> 8
(e) Ms. J. H. Heisen joined the Company in 1989 as Assistant Treasurer and
became Vice President, Investor Relations in 1990, Treasurer in 1991 and
Controller in 1995. She became a Member of the Executive Committee and Vice
President, Chief Information Officer in 1997.
(f) Mr. C. A. Koffmann joined the Company in 1989 as a Company Group Chairman.
He became a Member of the Executive Committee and Worldwide Chairman,
Consumer and Personal Care Group in 1995.
(g) Mr. J. T. Lenehan joined the Company in 1976 and became a Company Group
Chairman in 1993. He became a Member of the Executive Committee and
Worldwide Chairman, Consumer Pharmaceuticals and Professional Group in 1994.
(h) Mr. W. C. Weldon joined the Company in 1971 and held various positions
before becoming President of Ethicon Endo-Surgery in 1992 and Company Group
Chairman of Ethicon Endo-Surgery in 1995. He became a Member of the
Executive Committee and Worldwide Chairman, Pharmaceuticals Group in June
1998.
PART II
ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED SHAREOWNER
MATTERS
The information called for by this item is incorporated herein by reference
to the material captioned "Management's Discussion and Analysis of Results of
Operations and Financial Condition--Common Stock Market Prices and Cash
Dividends Paid" on page 25 of Johnson & Johnson's Annual Report to Shareowners
for fiscal year 1998.
ITEM 6. SELECTED FINANCIAL DATA
The information called for by this item is incorporated herein by reference
to the material captioned "Summary of Operations and Statistical Data 1988-1998"
on page 46 of Johnson & Johnson's Annual Report to Shareowners for fiscal year
1998.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The information called for by this item is incorporated herein by reference
to the narrative and tabular (but not the graphic) material included in the
material captioned "Management's Discussion and Analysis of Results of
Operations and Financial Condition" on pages 24 through 30 of Johnson &
Johnson's Annual Report to Shareowners for fiscal year 1998.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The information called for by this item is incorporated herein by reference
to the material captioned "Management's Discussion and Analysis of Results of
Operations and Financial Condition -- Financial Instruments" on page 26 of
Johnson & Johnson's Annual Report to Shareowners for fiscal year 1998.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The information called for by this item is incorporated herein by reference
to the Consolidated Financial Statements and the Notes thereto and the material
captioned "Independent Auditor's Report" on pages 31 through 44 of Johnson &
Johnson's Annual Report to Shareowners for fiscal year 1998.
ITEM 9. CHANGE IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
Not applicable.
6
<PAGE> 9
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The information called for by this item is incorporated herein by reference
to (a) the material under the caption "Election of Directors -- Nominees" on
pages 2 through 6 of Johnson & Johnson's Proxy Statement dated March 10, 1999,
(b) the material in Part I hereof under the caption "Executive Officers of the
Registrant" and (c) the material under the caption "Section 16(a) Beneficial
Ownership Reporting Compliance" on page 9 of Johnson & Johnson's Proxy Statement
dated March 10, 1999.
ITEM 11. EXECUTIVE COMPENSATION
The information called for by this item is incorporated herein by reference
to the following sections of Johnson & Johnson's Proxy Statement dated March 10,
1999: "Election of Directors -- Directors' Fees, Committees and Meetings" on
pages 7 through 8; "Compensation Committee Report on Executive Compensation" on
pages 9 through 12; "Shareowner Return Performance Graphs" on pages 12 through
13; and "Executive Compensation" on pages 14 through 17.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information called for by this item is incorporated herein by reference
to the material captioned "Election of Directors--Stock Ownership/Control" on
page 7 of Johnson & Johnson's Proxy Statement dated March 10, 1999.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Not applicable.
7
<PAGE> 10
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(a) The following documents are filed as part of this report
1. Financial Statements
The following Consolidated Financial Statements and the Notes thereto and
the Independent Auditor's Report on pages 31 through 44 of Johnson & Johnson's
Annual Report to Shareowners for fiscal year 1998 are incorporated herein by
reference:
Consolidated Balance Sheet at end of Fiscal Years 1998 and 1997
Consolidated Statement of Earnings for Fiscal Years 1998, 1997 and 1996
Consolidated Statement of Equity for Fiscal Years 1998, 1997 and 1996
Consolidated Statement of Cash Flows for Fiscal Years 1998, 1997 and
1996
Notes to Consolidated Financial Statements
Independent Auditor's Report
2. Financial Statement Schedules
Schedule II -- Valuation and Qualifying Accounts
Schedules other than those listed above are omitted because they are not
required or are not applicable.
3. Exhibits Required to be Filed by Item 60l of Regulation S-K
The information called for by this item is incorporated herein by reference
to the Exhibit Index in this report.
(b) Reports on Form 8-K
No reports on Form 8-K were filed during the last quarter of 1998.
8
<PAGE> 11
JOHNSON & JOHNSON AND SUBSIDIARIES
SCHEDULE II -- VALUATION AND QUALIFYING ACCOUNTS
FISCAL YEARS ENDED JANUARY 3, 1999, DECEMBER 28, 1997 AND DECEMBER 29, 1996
(DOLLARS IN MILLIONS)
<TABLE>
<CAPTION>
DEDUCTIONS FROM RESERVES
ADDITIONS ---------------------------------------------------
BALANCE AT CHARGED BALANCE
BEGINNING TO COSTS AND AT END
OF PERIOD EXPENSES(A) DESCRIPTION AMOUNT OF PERIOD
---------- ------------ ----------- ------ ---------
<S> <C> <C> <C> <C> <C>
1998
Reserves deducted from
accounts receivable, trade
Reserve for doubtful
accounts............... $152 39 Write-offs less recoveries..... 15
Currency adjustments........... (5) 181
Reserve for customer
rebates................ 164 978 Customer rebates allowed....... 993
Currency adjustments........... (8) 157
Cash discounts allowed......... 429
Reserve for cash
discounts.............. 42 431 Currency adjustments........... (3) 47
---- ----- ----- ---
$358 1,448 1,421 385
==== ===== ===== ===
1997
Reserves deducted from
accounts receivable, trade
Reserve for doubtful
accounts............... $141 49 Write-offs less recoveries..... 29
Currency adjustments........... 9 152
Reserve for customer
rebates................ 129 855 Customer rebates allowed....... 813
Currency adjustments........... 7 164
Cash discounts allowed......... 341
Reserve for cash
discounts.............. 39 352 Currency adjustments........... 8 42
---- ----- ----- ---
$309 1,256 1,207 358
==== ===== ===== ===
1996
Reserves deducted from
accounts receivable, trade
Reserve for doubtful
accounts............... $109 60 Write-offs less recoveries..... 27
Currency adjustments........... 1 141
Reserve for customer
rebates................ 115 686 Customer rebates allowed....... 671
Currency adjustments........... 1 129
Reserve for cash
discounts.............. 34 388 Cash discounts allowed......... 383 39
---- ----- ----- ---
$258 1,134 1,083 309
==== ===== ===== ===
</TABLE>
- ---------------
(A) Charges related to customer rebates and cash discounts are reflected as
reductions of sales to customers.
9
<PAGE> 12
SIGNATURES
Pursuant to the requirements of Section 13 of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date: March 22, 1999 JOHNSON & JOHNSON
--------------------------------------
(Registrant)
By /s/ R. S. LARSEN
------------------------------------
R. S. Larsen, Chairman, Board of
Directors
and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
--------- ----- ----
<C> <S> <C>
/s/ R. S. LARSEN Chairman, Board of Directors and March 22, 1999
- ------------------------------------------ Chief Executive Officer, and
R. S. Larsen Director (Principal Executive
Officer)
/s/ R. J. DARRETTA Vice President -- Finance March 25, 1999
- ------------------------------------------ (Principal Financial Officer)
R. J. Darretta
/s/ C. E. LOCKETT Controller March 23, 1999
- ------------------------------------------
C. E. Lockett
/s/ G. N. BURROW Director March 24, 1999
- ------------------------------------------
G. N. Burrow
/s/ J. G. COONEY Director March 24, 1999
- ------------------------------------------
J. G. Cooney
/s/ J. G. CULLEN Director March 29, 1999
- ------------------------------------------
J. G. Cullen
/s/ M. J. FOLKMAN Director March 25, 1999
- ------------------------------------------
M. J. Folkman
/s/ A. D. JORDAN Director March 23, 1999
- ------------------------------------------
A. D. Jordan
/s/ A. G. LANGBO Director March 24, 1999
- ------------------------------------------
A. G. Langbo
/s/ J. S. MAYO Director March 22, 1999
- ------------------------------------------
J. S. Mayo
</TABLE>
10
<PAGE> 13
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
--------- ----- ----
<C> <S> <C>
/s/ P. J. RIZZO Director March 22, 1999
- ------------------------------------------
P. J. Rizzo
/s/ H. B. SCHACHT Director March 24, 1999
- ------------------------------------------
H. B. Schacht
/s/ M. F. SINGER Director March 23, 1999
- ------------------------------------------
M. F. Singer
Director March , 1999
- ------------------------------------------
J. W. Snow
/s/ R. N. WILSON Vice Chairman, Board of Directors March 30, 1999
- ------------------------------------------ and Director
R. N. Wilson
</TABLE>
11
<PAGE> 14
REPORT OF INDEPENDENT AUDITORS
To the Shareowners and Board of Directors of
Johnson & Johnson:
Our report on the consolidated financial statements of Johnson & Johnson
and subsidiaries has been incorporated by reference in this Form 10-K from the
Johnson & Johnson 1998 Annual Report to Shareowners and appears on page 44
therein. In connection with our audits of such financial statements, we have
also audited the related financial statement schedule listed in the index in
Item 14 of this Form 10-K.
In our opinion, the financial statement schedule referred to above, when
considered in relation to the basic financial statements taken as a whole,
presents fairly, in all material respects, the information required to be
included therein.
/s/ PricewaterhouseCoopers LLP
PRICEWATERHOUSECOOPERS LLP
New York, New York
January 25, 1999
12
<PAGE> 15
EXHIBIT INDEX
<TABLE>
<CAPTION>
REG. S-K
EXHIBIT TABLE DESCRIPTION
ITEM NO. OF EXHIBIT
- ------------- -----------
<C> <S>
3(a)(i) Restated Certificate of Incorporation dated April 26,
1990 -- Incorporated herein by reference to Exhibit 3(a) of
the Registrant's Form 10-K Annual Report for the year ended
December 30, 1990.
3(a)(ii) Certificate of Amendment to the Restated Certificate of
Incorporation of the Company dated May 20,
1992 -- Incorporated herein by reference to Exhibit 3(a) of
the Registrant's Form 10-K Annual Report for the year ended
January 3, 1993.
3(a)(iii) Certificate of Amendment to the Restated Certificate of
Incorporation of the Company dated May 21,
1996 -- Incorporated herein by reference to Exhibit
3(a)(iii) of the Registrant's Form 10-K Annual Report for
the year ended December 29, 1996.
3(b) By-Laws of the Company, as amended and currently in
effect -- Incorporated herein by reference to Exhibit 3(b)
of the Registrant's Form 10-K Annual Report for the year
ended December 28, 1997.
4(a) Upon the request of the Securities and Exchange Commission,
the Registrant will furnish a copy of all instruments
defining the rights of holders of long term debt of the
Registrant.
10(a) Stock Option Plan for Non-Employee Directors -- Incorporated
herein by reference to Exhibit 10(a) of the Registrant's
Form 10-K Annual Report for the year ended December 29,
1996.*
10(b) 1995 Stock Option Plan (as amended) -- Filed with this
document.*
10(c) 1991 Stock Option Plan (as amended) -- Incorporated herein
by reference to Exhibit 10(c) of the Registrant's Form 10-K
Annual Report for the year ended December 28, 1997.*
10(d) 1986 Stock Option Plan (as amended) -- Incorporated herein
by reference to Exhibit 10(d) of the Registrant's Form 10-K
Annual Report for the year ended December 28, 1997.*
10(e) 1995 Stock Compensation Plan -- Incorporated herein by
reference to Exhibit 10(e) of the Registrant's Form 10-K
Annual Report for the year ended December 31, 1995.*
10(f) Executive Incentive Plan -- Incorporated herein by reference
to Exhibit 10(f) of the Registrant's Form 10-K Annual Report
for the year ended December 29, 1996.*
10(g) Domestic Deferred Compensation Plan (as
amended) -- Incorporated herein by reference to Exhibit
10(g) of the Registrant's Form 10-K Annual Report for the
year ended December 29, 1996.*
10(h) Deferred Fee Plan for Directors (as amended) -- Incorporated
herein by reference to Exhibit 10(h) of the Registrant's
Form 10-K Annual Report for the year ended December 29,
1996.*
10(i) Executive Income Deferral Plan -- Incorporated herein by
reference to Exhibit 10(i) of the Registrant's Form 10-K
Annual Report for the year ended December 28, 1997.*
10(j) Excess Savings Plan -- Incorporated herein by reference to
Exhibit 10(j) of the Registrant's Form 10-K Annual Report
for the year ended December 29, 1996.*
10(k) Supplemental Retirement Plan -- Incorporated herein by
reference to Exhibit 10(h) of the Registrant's Form 10-K
Annual Report for the year ended January 3, 1993.*
10(l) Executive Life Insurance Plan -- Incorporated herein by
reference to Exhibit 10(i) of the Registrant's Form 10-K
Annual Report for the year ended January 3, 1993.*
12 -- Statement of Computation of Ratio of Earnings to Fixed
Charges -- Filed with this document.
</TABLE>
13
<PAGE> 16
<TABLE>
<CAPTION>
REG. S-K
EXHIBIT TABLE DESCRIPTION
ITEM NO. OF EXHIBIT
- ------------- -----------
<C> <S>
13 -- Pages 24 through 46 of the Company's Annual Report to
Shareowners for fiscal year 1998 (only those portions of the
Annual Report incorporated by reference in this report are
deemed "filed") -- Filed with this document.
21 -- Subsidiaries -- Filed with this document.
23 -- Consent of Independent Auditors -- Filed with this
document.
27 -- Financial Data Schedule for Year Ended January 3,
1999 -- Filed with this document.
99(a) -- Annual Reports on Form 11-K for the Johnson & Johnson
Savings Plans, to be filed on or before June 30, 1999.
99(b) -- Cautionary Statement pursuant to Private Securities
Litigation Reform Act of 1995: "Safe Harbor" for
Forward-Looking Statements -- Filed with this document.
</TABLE>
- ---------------
* Management contracts and compensatory plans and arrangements required to be
filed as Exhibits to this form pursuant to Item 14(c) of the report.
A copy of any of the Exhibits listed above will be provided without charge
to any shareowner submitting a written request specifying the desired exhibit(s)
to the Secretary at the principal executive offices of the Company.
14
<PAGE> 1
EXHIBIT 10(b)
JOHNSON & JOHNSON
1995 STOCK OPTION PLAN
(EFFECTIVE APRIL 27, 1995, AS AMENDED NOVEMBER 30, 1995, DECEMBER 4, 1997 AND
JUNE 8, 1998)
1. PURPOSE
The purpose of the Johnson & Johnson 1995 Stock Option Plan (the "Plan") is
to promote the interests of Johnson & Johnson (the "Company") by ensuring
continuity of management and increased incentive on the part of officers and
executive employees responsible for major contributions to effective management,
through facilitating their acquisition of an equity interest in the Company on
reasonable terms.
2. ADMINISTRATION
The Plan shall be administered by the Compensation Committee of the Board
of Directors (the "Committee"). The Committee shall consist of not less than
three directors. No person shall be eligible to serve as a member of such
Committee unless such person is a "disinterested person" within the meaning of
Rule 16b-3 of the General Rules and Regulations under the Securities Exchange
Act of 1934, as amended, and an "outside director" within the meaning of Section
162(m) of the Internal Revenue Code of 1986, as amended (the "Internal Revenue
Code"). Committee members shall not be eligible to participate in the Plan while
members of the Committee. It shall have the power to select optionees, to
establish the number of shares and other terms applicable to each such option,
to construe the provisions of the Plan, and to adopt rules and regulations
governing the administration of the Plan.
The Board of Directors, within its discretion, shall have authority to
amend the Plan and the terms of any option issued hereunder without the
necessity of obtaining further approval of the stockholders, unless such
approval is required by law.
3. ELIGIBILITY
Those eligible to participate in the Plan will be selected by the Committee
from the following:
(1) Directors who are employees of the Company or its domestic
subsidiaries (excluding members from time to time of the Committee).
(2) Officers and other key employees of the Company and its domestic
subsidiaries.
(3) Key employees of subsidiaries outside the United States.
(4) Key employees of a joint venture operation of the Company or its
subsidiaries and key employees of joint venture partners who are assigned
to such a joint venture.
In all cases, optionees shall be selected on the basis of demonstrated
ability to contribute substantially to the effective management of the Company.
In no event shall an option be granted to any individual who, immediately
after such option is granted, is considered to own stock possessing more than
10% of the combined voting power of all classes of stock of Johnson & Johnson or
any of its subsidiaries within the meaning of Section 422 of the Internal
Revenue Code.
1
<PAGE> 2
4. ALLOTMENT OF SHARES
A maximum of 56,000,000 authorized but unissued shares of the Common Stock
of the Company (par value $1.00) will be allotted to the Plan, subject to the
required approval by the stockholders. The total number of shares which may be
awarded under the Plan to any optionee in any one year shall not exceed 5% of
the total shares allotted to the Plan. The Committee may, in its discretion, use
Treasury shares in lieu of authorized but unissued shares for the options. To
the extent this is done, the number of authorized but unissued shares to be used
for the Plan will be reduced.
Shares covered by options which lapse or have been terminated during the
duration of this Plan may be reallocated by the Committee.
5. EFFECTIVE DATE AND TERM OF PLAN
The Plan shall become effective on April 27, 1995. No option shall be
granted pursuant to this Plan later than April 26, 2000, but options theretofore
granted may extend beyond that date in accordance with their terms.
6. TERMS AND CONDITIONS
A. All Options
The following shall apply to all options granted under the Plan:
(i) Option Price
The option price per share for each stock option shall be
determined by the Committee and shall not be less than the fair market
value on the date the option is granted. The fair market value shall be
determined as prescribed by the Internal Revenue Code and Regulations.
(ii) Time of Exercise of Option
The Committee shall establish the time or times within the option
period when the stock option may be exercised in whole or in such parts
as may be specified from time to time by the Committee. With respect to
an optionee whose employment has terminated by reason of death,
disability or retirement, the Committee may in its discretion accelerate
the time or times when any particular stock option held by said optionee
may be so exercised so that such time or times are earlier than those
originally provided in said option. In all cases exercise of a stock
option shall be subject to the provisions of Section 6B(ii) or 6C(iii),
as the case may be. The Committee shall determine, either at the time of
grant or later whether, and to what extent and under what circumstances,
the transfer of shares issuable in connection with the exercise of a
non-qualified option may be deferred at the election of the optionee.
(iii) Payment
The entire option price may be paid at the time the option is
exercised. When an option is exercised prior to termination of
employment, the Committee shall have the discretion to arrange for the
payment of such price, in whole or in part, in installments. In such
cases, the Committee shall obtain such evidence of the optionee's
obligation, establish such interest rate and require such security as it
may deem appropriate for the adequate protection of the Company.
(iv) Non-Transferability of Option
Unless otherwise specified by the Committee to the contrary, an
option by its terms shall not be transferable by the optionee otherwise
than by will or by the laws of descent and distribution and
2
<PAGE> 3
shall be exercisable during the optionee's lifetime only by the
optionee. The Committee may, in the manner established by the Committee,
provide for the transfer, without payment of consideration, of a
non-qualified option by an optionee to a member of the optionee's
immediate family or to a trust or partnership whose beneficiaries are
members of the optionee's immediate family. In such case, the option
shall be exercisable only by such transferee. For purposes of this
provision, an optionee's "immediate family" shall mean the holder's
spouse, children and grandchildren.
(v) Adjustment in Event of Recapitalization of the Company
In the event of a reorganization, recapitalization, stock split,
stock dividend, combination of shares, merger, consolidation, rights
offering, or any other change in the corporate structure or shares of
the Company, the Board of Directors shall make such adjustment as it may
deem equitably required in the number and kind of shares authorized by
and for the Plan, in the number and kind of shares covered by the
options granted, in the number of shares which may be awarded to an
optionee in any one year, and in the option price.
B. Non-Qualified Stock Options
The Committee may, in its discretion, grant options under the Plan which,
in whole or in part, do not qualify as incentive stock options under Section 422
of the Internal Revenue Code. In addition to the terms and conditions set forth
in Section 6A above, the following terms and conditions shall govern any option
(or portion thereof) to the extent that it does not so qualify.
(i) Form of Payment
Payment of the option price of any option (or portion thereof) not
qualifying as an incentive stock option shall be made in cash or, in the
discretion of the Committee, in the Common Stock of the Company valued
at its fair market value (as the same shall be determined by the
Committee), or a combination of such Common Stock and cash.
(ii) Rights after Termination of Employment
(a) For options granted prior to July 1, 1998
In the event of termination of employment due to any cause
including death, disability or retirement, rights to exercise the stock
option shall cease, except for those which have accrued to the date of
termination, unless the Committee shall otherwise specify. These rights
shall remain exercisable for a period of three months, or such longer
period (not to exceed three years) as the Committee shall provide,
following termination for any cause other than death, disability or
retirement and for a period of three years following termination due to
death, disability or retirement, unless the Committee otherwise
specifies. The Committee may, in its discretion, extend the period
within which any particular option may be exercised beyond the
expiration date originally provided in said option. However, no stock
option shall, in any event, be exercised after the expiration of the
full term of the option.
(b) For options granted on or after July 1, 1998:
(1) In the event of termination of employment due to any cause
other than death, disability or retirement, rights to exercise the stock
option shall cease, except for those which have accrued to and including
the date of termination, unless the Committee shall otherwise specify.
These rights shall
3
<PAGE> 4
remain exercisable for a period of three (3) months, or such longer
period (not to exceed three (3) years) as the Committee shall provide.
(2) In the event of termination of employment due to death or
disability, rights to exercise the stock option shall cease, except for
those which have accrued to and including the date of termination,
unless the Committee shall otherwise specify. These rights shall remain
exercisable for a period of three (3) years, or such longer period (not
to exceed the term of the option) as the Committee shall provide.
Notwithstanding the above, in the event such termination of
employment due to death or disability occurs with optionee having at
least ten (10) years of service, any unexercised or unexercisable
portion of the stock option may be exercised in whole or in part during
the remaining term of the Option at such times and to the extent the
optionee could have exercised such stock option had the optionee's
employment not terminated.
(3) In the event of retirement (unrelated to termination for cause,
as defined below, which shall be governed by the provisions of (1)
above) rights to exercise the stock option shall cease, except for those
which have accrued to and including the date of termination unless the
Committee shall otherwise specify. These rights shall remain exercisable
for a period of three (3) years, or such longer period (not to exceed
the term of the option) as the Committee shall provide, provided,
however, that in the event the Optionee is employed by a competitor (as
defined below) within two (2) years from the date of such retirement, no
rights may be exercisable beyond a date which is three (3) months after
the commencement of such employment with a competitor.
Notwithstanding the above, in the event such retirement (unrelated
to termination for cause which shall be governed by the provisions of
(1) above) occurs with optionee having at least ten (10) years of
service, any unexercised or unexercisable portion of the stock option
may be exercised in whole or in part during the remaining term of the
stock option at such times and to the extent the optionee could have
exercised such stock option had the optionee's employment not
terminated, provided, however, that in the event the optionee is
employed by a competitor within two (2) years from the date of such
retirement, (i) any unexercisable portion of the stock option shall
terminate immediately and (ii) no rights may be exercisable beyond a
date which is three (3) months after the commencement of such employment
with a competitor.
(4) No stock option shall, in any event, be exercised after the
expiration of the full term of the option. In addition, any stock option
granted within six (6) months of termination of employment due to any
cause shall be void unless the Committee shall otherwise provide.
(5) As used in the Plan:
(i) The term "termination for cause" shall mean optionee's
termination by the Company in connection with the violation of any
federal or state law, dishonesty, the willful and deliberate failure
on the part of an optionee to perform his/her employment duties in
any material respect or such other events, including the existence of
a conflict of interest, as the Management Compensation Committee may
determine. Such committee shall have the sole discretion to determine
whether a "termination for cause" exists, and its determination shall
be final.
(ii) The term "employed by a competitor" shall mean the
optionee's engaging in any activity or providing services, whether as
director, employee, advisor, consultant or otherwise, for any
corporation or other entity which is a competitor of the Company. The
Management
4
<PAGE> 5
Compensation Committee shall have the sole discretion to determine if
an optionee is "employed by a competitor", and its determination
shall be final.
(iii) Period of Option
The exercise period of each non-qualified stock option shall be
specified by the Committee at the time of grant.
C. Incentive Stock Options
The Committee may, in its discretion, grant options under the Plan which
qualify in whole or in part as incentive stock options under Section 422 of the
Internal Revenue Code. In addition to the terms and conditions set forth in
Section 6A above, the following terms and conditions shall govern any option (or
portion thereof) to the extent that it so qualifies:
(i) Maximum Fair Market Value of Incentive Stock Options
The aggregate fair market value (determined as of the time such
option is granted) of the Common Stock for which any optionee may have
stock options which first became vested in any calendar year (under all
incentive stock option plans of the Company and its parent and
subsidiary corporations) shall not exceed $100,000.
(ii) Form of Payment
Payment of the option price for incentive stock options shall be
made in cash or in the Common Stock of the Company valued at its fair
market value (as the same shall be determined by the Committee), or a
combination of such Common Stock and cash. Where payment of the option
price is to be made with Common Stock acquired under a Company
compensation plan (within the meaning of paragraph 11(g) of Opinion No.
25 of the Accounting Principles Board), such Common Stock will not be
accepted as payment unless the optionee has beneficially owned such
Common Stock for at least six months (increased to one year if such
Common Stock was acquired under an incentive stock option) prior to such
payment.
(iii) Rights after Termination of Employment
(a) For options granted prior to July 1, 1998
In the event of termination of employment due to any cause
including death, disability or retirement, rights to exercise the stock
option shall cease, except for those which have accrued to the date of
termination, unless the Committee shall otherwise specify. These rights
shall remain exercisable for a period of three months, or such longer
period (not to exceed three years) as the Committee shall provide,
following termination for any cause other than death, disability or
retirement and for a period of three years following termination due to
death, disability or retirement, unless the Committee otherwise
specifies. However, no incentive stock option shall, in any event, be
exercised after the expiration of 10 years from the date such option is
granted, or such earlier date as may be specified in the option.
(b) For incentive stock options granted on or after July 1, 1998:
(1) In the event of termination of employment due to any cause
other than death, disability or retirement, rights to exercise the stock
option shall cease, except for those which have accrued to and including
the date of termination, unless the Committee shall otherwise specify.
These rights shall
5
<PAGE> 6
remain exercisable for a period of three (3) months, or such longer
period (not to exceed three (3) years) as the Committee shall provide.
(2) In the event of termination of employment due to death or
disability, rights to exercise the stock option shall cease, except for
those which have accrued to and including the date of termination,
unless the Committee shall otherwise specify. These rights shall remain
exercisable for a period of three (3) years, or such longer period (not
to exceed the term of the option) as the Committee shall provide.
Notwithstanding the above, in the event such termination of
employment due to death or disability occurs with optionee having at
least ten (10) years of service, any unexercised or unexercisable
portion of the stock option may be exercised in whole or in part during
the remaining term of the Option at such times and to the extent the
optionee could have exercised such stock option had the optionee's
employment not terminated.
(3) In the event of retirement (unrelated to termination for cause
(as defined in Section 6B(ii)(b)(5) above, which shall be governed by
the provisions of (1) above) rights to exercise the stock option shall
cease, except for those which have accrued to and including the date of
termination unless the Committee shall otherwise specify. These rights
shall remain exercisable for a period of three (3) years, or such longer
period (not to exceed the term of the option) as the Committee shall
provide, provided, however, that in the event the Optionee is employed
by a competitor (as defined in Section 6B(ii)(b)(5) above) within two
(2) years from the date of such retirement, no rights may be exercisable
beyond a date which is three (3) months after the commencement of such
employment with a competitor.
Notwithstanding the above, in the event such retirement (unrelated
to termination for cause which shall be governed by the provisions of
(1) above) occurs with optionee having at least ten (10) years of
service, any unexercised or unexercisable portion of the stock option
may be exercised in whole or in part during the remaining term of the
stock option at such times and to the extent the optionee could have
exercised such stock option had the optionee's employment not
terminated, provided, however, that in the event the optionee is
employed by a competitor within two (2) years from the date of such
retirement, (i) any unexercisable portion of the stock option shall
terminate immediately and (ii) no rights may be exercisable beyond a
date which is three (3) months after the commencement of such employment
with a competitor.
(4) No incentive stock option shall, in any event, be exercised
after the expiration of 10 years from the date such option is granted,
or such earlier date as may be specified in the option. In addition, any
stock option granted within six (6) months of termination of employment
due to any cause shall be void unless the Committee shall otherwise
provide.
(iv) Period of Option
The exercise period of each incentive stock option by its terms
shall not be more than 10 years from the date the option is granted as
specified by the Committee.
6
<PAGE> 1
EXHIBIT 12
JOHNSON & JOHNSON AND SUBSIDIARIES
STATEMENT OF COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES(1)
(DOLLARS IN MILLIONS)
<TABLE>
<CAPTION>
FISCAL YEAR ENDED
--------------------------------------------------------------------
JANUARY 3, DECEMBER 28, DECEMBER 29, DECEMBER 31, JANUARY 1,
1999(2) 1997 1996 1995 1995
---------- ------------ ------------ ------------ ----------
<S> <C> <C> <C> <C> <C>
Determination of Earnings:
Earnings Before Provision for Taxes
on Income......................... $4,269 4,576 4,033 3,317 2,681
Fixed Charges........................ 190 198 204 219 234
------ ------ ------ ----- -----
Total Earnings as Defined.... $4,459 4,774 4,237 3,536 2,915
====== ====== ====== ===== =====
Fixed Charges and Other:
Rents................................ 80 78 79 76 92
Interests............................ 110 120 125 143 142
------ ------ ------ ----- -----
Fixed Charges................ 190 198 204 219 234
Capitalized Interest................. 71 40 55 70 44
------ ------ ------ ----- -----
Total Fixed Charges.......... $ 261 238 259 289 278
====== ====== ====== ===== =====
Ratio of Earnings to Fixed Charges..... 17.08 20.06 16.36 12.24 10.49
====== ====== ====== ===== =====
</TABLE>
- ---------------
(1) The ratio of earnings to fixed charges represents the historical ratio of
the Company and is calculated on a total enterprise basis. The ratio is
computed by dividing the sum of earnings before provision for taxes and
fixed charges (excluding capitalized interest) by fixed charges. Fixed
charges represent interest (including capitalized interest) and amortization
of debt discount and expense and the interest factor of all rentals,
consisting of an appropriate interest factor on operating leases.
(2) 1998 earnings include charges related to restructuring of $613 million and
in-process research and development charges, relating primarily to the DePuy
acquisition, of $164 million. Excluding the effect of these charges, the
ratio of earnings to fixed charges would have been 20.06.
15
<PAGE> 1
EXHIBIT 13
Management's Discussion and Analysis of Results of Operations and Financial
Condition
Overview
Record 1998 sales of $23.66 billion, an increase over 1997 of 4.5%, marked the
sixty-sixth consecutive year of positive sales growth. The Company achieved this
increase despite the impact of the stronger dollar that depressed sales by 2.5%.
During the fourth quarter of 1998, the Company completed the acquisition of
DePuy, Inc. and approved a reconfiguration plan for its manufacturing facilities
worldwide. As a result, net earnings included special charges of $610 million
for the cost of purchased In-Process Research and Development (IPR&D) primarily
related to the DePuy acquisition as well as restructuring costs related to the
reconfiguration plan. The objective of the reconfiguration plan was to enhance
worldwide operating efficiencies. For detailed discussion of this plan, see Note
15 and 17. Reported net earnings decreased by 7.4% to $3.06 billion. Prior to
the effect of the special charges, net earnings increased 11.1% over 1997 and
the net income margin for 1998 was a record high of 15.5%.
The Company's investment in research and development continues to drive
sales of innovative products. In 1998, $2.3 billion or 9.6% of sales was
invested in research and development. This level of investment, the highest in
the Company's history, reflects the Company's continued commitment to achieving
significant advances in health care through the discovery and development of
innovative, knowledge-based, cost effective products that prolong and enhance
the quality of life.
In 1998, the Company continued to improve operating margins. The gross
profit margin, excluding special charges, improved from 68.4% to 68.6% while
selling, marketing and administrative expenses as a percent to sales dropped
from 38.5% to 37.7%.
Cash from operations in 1998 was $4.89 billion and served as the primary
source of funding to finance capital investments of $1.5 billion, dividend
distribution of $1.3 billion and the purchase of treasury stock of $.9 billion,
with the remaining cash used to partially fund the DePuy acquisition. Cash
dividends paid to shareowners in 1998 increased by 14.1% over 1997 and
represented the thirty-sixth consecutive year of dividend increases.
Total equity market capitalization was $112.7 billion, an increase of
29.1% over 1997, while the percentage return on average shareowners' equity,
excluding the impact of special charges, was 27.6% in 1998.
The worldwide health care market continues to be transformed as customers
have become more knowledgeable and demand even greater value. Simultaneously,
the marketplace has become increasingly more competitive. The Company believes
that it is well positioned to meet these challenges by providing innovative
products as demonstrated by the Company's commitment to research and
development. In addition, dedicated employees along with strong Credo values and
decentralized management structure enable the Company to provide its customers
with value creating, innovative products and services.
Sales and Earnings
In 1998, worldwide sales increased 4.5% to $23.66 billion compared to increases
of 4.7% in 1997 and 14.7% in 1996. Excluding the impact of foreign currencies,
worldwide sales increased 7.0% in 1998, 8.7% in 1997 and 16.5% in 1996.
Sales to Customers
- --------------------------------------------------------------------------------
[GRAPHIC OMITTED]
- --------------------------------------------------------------------------------
Worldwide net earnings for 1998 including the impact of the Restructuring
and IPR&D charges were $3.06 billion, reflecting a 7.4% decrease from 1997.
Worldwide net earnings per share for 1998 equaled $2.23 per share, a decrease of
7.5% from the $2.41 net earnings per share in 1997.
Worldwide net earnings for 1998 excluding the impact of the Restructuring
and IPR&D charges were $3.67 billion, reflecting an 11.1% increase over 1997.
Excluding the impact of these charges, worldwide net earnings per share for 1998
equaled $2.67 per share, an increase of 10.8% over the $2.41 net earnings per
share in 1997. The income margin for 1998, excluding the impact of these charges
was a record 15.5%, up from 14.6% in 1997.
Worldwide net earnings for 1997 were $3.30 billion, or net earnings per
share of $2.41, representing an increase over 1996 of 13.7%. In 1996, worldwide
net earnings were $2.89 billion, or net earnings per share of $2.12 on a
split-adjusted basis, representing an increase over 1995 of 16.5%.
Average diluted shares of common stock outstanding in 1998 and 1997 were
1.37 billion compared with 1.36 billion in 1996.
Net Earnings
- --------------------------------------------------------------------------------
[GRAPHIC OMITTED]
- --------------------------------------------------------------------------------
Sales by domestic companies were $12.56 billion in 1998, $11.76 billion in 1997
and $10.9 billion in 1996. This represents an increase of 6.8% in 1998, 7.9% in
1997 and 18.6% in 1996. The strong performance of products introduced in the
past few years and the continued expansion of base businesses resulted in the
sales increase in 1998.
24
<PAGE> 2
Sales by international companies were $11.1 billion in 1998, $10.87
billion in 1997 and $10.72 billion in 1996. This represents an increase of 2.1%
in 1998, 1.4% in 1997 and 11.1% in 1996. Excluding the impact of the foreign
currency fluctuations over the past three years, international company sales
increased 7.3% in 1998, 9.5% in 1997 and 14.6% in 1996.
All geographic areas throughout the world posted solid operational gains
during 1998. Excluding the effect of exchange rate fluctuations of the U.S.
dollar on foreign currencies, sales increased 10.3% in Europe, 5.7% in the
Western Hemisphere (excluding the U.S.) and 8.8% in the Asia-Pacific, Africa
regions.
The Company achieved an annual compound growth rate of 10.2% for worldwide
sales for the ten-year period since 1988 with domestic sales growing at a rate
of 10.6% and international sales growing at a rate of 9.6%. For the same
ten-year period, excluding the impact of special charges in 1998, worldwide net
earnings achieved an annual growth rate of 14.2%, while earnings per share grew
at a rate of 14.3%. For the last five years, the annual compound growth rate for
sales was 10.8%. Excluding the special charges, the annual compound growth rate
for net earnings was 15.5% and the annual compound growth rate for earnings per
share was 14.4%.
Common Stock Market Prices
The Company's common stock is listed on the New York Stock Exchange under the
symbol JNJ. The approximate number of shareowners of record at year-end 1998 was
165,900. The composite market price ranges for Johnson & Johnson common stock
during 1998 and 1997 were:
<TABLE>
<CAPTION>
1998 1997
----------------------------------------------------
High Low High Low
- --------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
First quarter $76 1/2 63 3/8 62 3/4 48 5/8
Second quarter 77 7/8 67 66 7/8 51 1/8
Third quarter 80 3/4 68 1/4 65 7/8 55 1/8
Fourth quarter 89 3/4 72 5/8 67 5/16 52 5/8
Year-end close 83 7/8 64 7/8
</TABLE>
Cash Dividends Paid
The Company increased its dividends in 1998 for the thirty-sixth consecutive
year. Cash dividends paid were $.97 per share in 1998 compared with dividends of
$.85 per share in 1997 and $.735 per share in 1996. The dividends were
distributed as follows:
<TABLE>
<CAPTION>
1998 1997 1996
- --------------------------------------------------------------------------------
<S> <C> <C> <C>
First quarter $.22 .19 .165
Second quarter .25 .22 .19
Third quarter .25 .22 .19
Fourth quarter .25 .22 .19
-------------------------
Total $.97 .85 .735
=========================
</TABLE>
On December 3, 1998, the Board of Directors declared a regular cash dividend of
$.25 per share, paid on March 9, 1999 to shareowners of record on February 11,
1999.
The Company expects to continue the practice of paying regular cash
dividends.
Costs and Expenses
Research activities represent a significant part of the Company's business.
These expenditures relate to the development of new products, improvement of
existing products, technical support of products and compliance with
governmental regulations for the protection of the consumer. Worldwide costs of
research activities, excluding the write-off of IPR&D primarily in connection
with the acquisition of DePuy, were as follows:
<TABLE>
<CAPTION>
(Millions of Dollars) 1998 1997 1996
- --------------------------------------------------------------------------------
<S> <C> <C> <C>
Research expense $2,269 2,140 1,905
Percent increase over
prior year 6.0% 12.3% 16.6%
Percent of sales 9.6 9.5 8.8
</TABLE>
Research expense as a percent of sales for the Pharmaceutical segment was
15.8% for 1998, 16.7% for 1997 and 15.2% in 1996, while averaging 6.1%, 5.7% and
5.6% in the other two segments.
Research Expense
- --------------------------------------------------------------------------------
[GRAPHIC OMITTED]
- --------------------------------------------------------------------------------
Advertising expenses, which are comprised of television, radio and print
media, were $1.19 billion in 1998 and $1.26 billion in both 1997 and 1996.
Additionally, significant expenditures were incurred for promotional activities
such as couponing and performance allowances.
The Company believes that its operations comply in all material respects
with applicable environmental laws and regulations. The Company or its
subsidiaries are parties to a number of proceedings brought under the
Comprehensive Environmental Response, Compensation and Liability Act, commonly
known as Superfund, and comparable state laws, in which primary relief sought is
the cost of past and future remediation. While it is not feasible to predict or
determine the outcome of these proceedings, in the opinion of the Company, such
proceedings would not have a material adverse effect on the results of
operations, cash flows or financial position of the Company.
Worldwide sales do not reflect any significant degree of seasonality;
however, spending has been heavier in the fourth quarter of each year than in
other quarters. This reflects increased spending decisions, principally for
advertising and research grants.
The worldwide effective income tax rate was 28.3% in 1998, 27.8% in 1997
and 28.4% in 1996. The increase in the 1998 worldwide effective tax rate was
primarily due to the Company's charge for IPR&D in the fourth quarter of 1998,
which is not tax deductible. Refer to Note 6 of the Notes to Consolidated
Financial Statements for additional information.
A summary of operations and related statistical data for the years
1988-1998 can be found on page 46.
25
<PAGE> 3
Distribution of Sales Revenues
The distribution of sales revenues for 1998, 1997 and 1996 were:
<TABLE>
<CAPTION>
1998 1997 1996
- --------------------------------------------------------------------------------
<S> <C> <C> <C>
Employment costs 23.9% 23.8% 24.4%
Cost of materials
and services 48.9 50.8 51.8
Depreciation and
amortization
of property
and intangibles 5.3 4.7 4.6
Taxes other than payroll 6.4 6.1 5.8
Earnings reinvested
in business 7.4 9.6 8.9
Cash dividends paid 5.5 5.0 4.5
Restructuring/IPR&D 2.6 -- --
- --------------------------------------------------------------------------------
</TABLE>
Liquidity and Capital Resources
Cash generated from operations and selected borrowings provide the major sources
of funds for the growth of the business, including working capital, additions to
property, plant and equipment and acquisitions. Cash and current marketable
securities totaled $2.58 billion at the end of 1998 as compared with $2.90
billion at the end of 1997.
Total unused credit available to the Company approximates $3.2 billion,
including $1.2 billion of credit commitments with various worldwide banks, $800
million of which expires on October 1, 1999 and $400 million on October 6, 2003.
In 1998 the Company issued $60 million of 5.12% notes due 2003, the
proceeds of which were used for general corporate purposes. The Company issued
no medium term notes during 1998. At January 3, 1999, the Company had $2.29
billion remaining on its shelf registration of $2.59 billion. A summary of
borrowings can be found on page 36.
Total borrowings at the end of 1998 and 1997 were $4.02 billion and $1.84
billion, respectively. The increase in borrowings was attributable to financing
the acquisition of DePuy. In 1998 net debt (debt net of cash and current
marketable securities) was 9.6% of net capital (shareowners' equity and net
debt). In 1997 net cash (cash and current marketable securities net of debt) was
$1.06 billion. Total debt represented 22.8% of total capital (shareowners'
equity and total debt) in 1998 and 13.0% of total capital in 1997. Shareowners'
equity per share at the end of 1998 was $10.11 compared with $9.19 at year-end
1997, an increase of 10.0%.
Financial Instruments
The Company uses financial instruments to manage the impact of interest rate and
foreign exchange rate changes on earnings and cash flows. Accordingly, the
Company enters into forward foreign exchange contracts to protect the value of
existing foreign currency assets and liabilities and to hedge future foreign
currency product costs. Gains or losses on these contracts are offset by the
gains or losses on the underlying transactions. A 10% appreciation of the U.S.
Dollar from January 3, 1999 market rates would increase the unrealized value of
the Company's forward contracts by $225 million. Conversely, a 10% depreciation
of the U.S. Dollar from January 3, 1999 market rates would decrease the
unrealized value of the Company's forward contracts by $259 million. In either
scenario, the gain or loss on the forward contract is offset by the gain or loss
on the underlying transaction and therefore has no impact on future earnings and
cash flows.
The Company enters into interest rate and currency swap contracts to
manage the Company's exposure to interest rate changes and hedge foreign
currency denominated debt. The impact of a 1% change in interest rates on the
Company's interest rate sensitive financial instruments is immaterial.
The Company does not enter into financial instruments for trading or
speculative purposes. Further, the Company has a policy of only entering into
contracts with parties that have at least an "A" (or equivalent) credit rating.
The counterparties to these contracts are major financial institutions and the
Company does not have significant exposure to any one counterparty. Management
believes the risk of loss is remote and in any event would be immaterial.
Changing Prices and Inflation
Johnson & Johnson is aware that its products are used in a setting where, for
more than a decade, policymakers, consumers, and businesses have expressed
concern about the rising cost of health care. In response to these concerns,
Johnson & Johnson has a long-standing policy of pricing products responsibly.
For the period 1980-1998, in the United States, the weighted average compound
annual growth rate of Johnson & Johnson price increases for health care products
(prescription and over-the-counter drugs, hospital and professional products)
was below the U.S. Consumer Price Index (CPI) for the period.
Inflation rates, even though moderate in many parts of the world during
1998, continue to have an effect on worldwide economies and, consequently, on
the way companies operate. In the face of increasing costs, the Company strives
to maintain its profit margins through cost reduction programs, productivity
improvements and periodic price increases.
YEAR 2000
The YEAR 2000 problem may occur when computer systems use the two digits "00"to
represent the year 2000. As a result, these systems may not process dates after
1999, causing system errors or failures. The Company has had a program in place
since the fourth quarter of 1996 to address YEAR 2000 issues in our critical
business areas relating to information management systems (IM), non-IM systems
with embedded technology, products, suppliers and customers. A report on this
program's process has been provided to the Board of Directors.
The Company has completed its review of critical IM systems and is in the
process of correcting issues as necessary. These corrective actions will be
substantially complete by the second quarter of 1999. Additionally, the Company
is reviewing all other automated systems including non-IM systems with embedded
technology and adjusting these systems as needed. This phase is also expected to
be completed by the end of the second quarter of 1999.
26
<PAGE> 4
The Company has made substantial progress in its assessment and testing
plan for all its products. The Company has substantially completed this plan at
year-end 1998 with full completion expected by the third quarter of 1999.
The Company's ability to implement its YEAR 2000 program and the related
non-implementation costs cannot be accurately determined at this time. Although
a failure to completely correct one system may adversely affect other systems,
the Company does not believe that these effects are likely. A material adverse
effect on the financial condition and results of operations of the business may
occur if a significant number of such failures should take place, requiring
manual backup methods and related costs.
The Company has been reviewing and has requested assurances on the status
of YEAR 2000 readiness of its critical suppliers. Many of these suppliers
however, have either declined to provide or have limited their assurances on the
status of their YEAR 2000 readiness. The Company has established a plan for
continued monitoring of critical suppliers during 1999.
Although the Company has contacted major customers to assess the status of
their YEAR 2000 issues, their YEAR 2000 readiness is unclear. If a significant
number of suppliers and customers experience disruptions as a result of YEAR
2000 issues, this could have a material adverse effect on the financial position
and results of operations of the Company.
The Company is formulating contingency plans to deal with the impact of
YEAR 2000 problems on critical suppliers and major customers. For critical
suppliers, these plans may include identifying the availability of alternate
utilities and raw material supply sources as well as increasing levels of
inventory. To mitigate the effects of lack of YEAR 2000 readiness of major
customers, the Company has few alternatives other than manual methods.
Regardless of the contingency plans developed, there can be no assurance that
these plans will address all YEAR 2000 problems or that implementation of these
plans will be successful.
The total cost of addressing the Company's YEAR 2000 readiness issues is
not expected to be material to the Company's financial condition or results of
operations. Since the initiation of the YEAR 2000 readiness program in 1996, the
Company estimates that it has expensed approximately $125 million in internal
and external costs on a pre-tax basis. The Company currently estimates that the
total costs for addressing YEAR 2000 readiness will approximate $200 million on
a pre-tax basis. These costs are being expensed as incurred and are funded
through operating cash flows. No projects material to the financial condition or
results of operations of the Company have been deferred or delayed as a result
of the Company's YEAR 2000 program.
New Accounting Pronouncement
In June 1998, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 133 "Accounting for Derivative Instruments
and Hedging Activities" (FAS 133). This standard is effective for all fiscal
quarters of fiscal years beginning after June 15, 1999.
FAS 133 requires that all derivative instruments be recorded on the
balance sheet at their respective fair values. Changes in the fair value of
derivatives are recorded each period in current earnings or other comprehensive
income, depending on the designation of the hedge transaction. For fair-value
hedge transactions in which the Company is hedging changes in an asset's,
liability's or firm commitment's fair value, changes in the fair value of the
derivative instrument will generally be offset by changes in the hedged item's
fair value. For cash flow hedge transactions in which the Company is hedging the
variability of cash flows related to a variable rate asset, liability or
forecasted transaction, changes in the fair value of the derivative instrument
will be reported in other comprehensive income. The gains and losses on the
derivative instrument that are reported in other comprehensive income will be
recognized in earnings in the periods in which earnings are impacted by the
variability of the cash flows of the hedged item.
The Company will adopt FAS 133 in the first quarter of 2000 and does not
expect it to have a material effect on the Company's results of operations, cash
flows or financial position.
Segments of Business
Financial information for the Company's three worldwide business segments is
summarized below. Refer to page 45 for additional information on segments of
business.
Sales by Segment of Business
- --------------------------------------------------------------------------------
[GRAPHIC OMITTED]
- --------------------------------------------------------------------------------
<TABLE>
<CAPTION>
Sales Increase
-------------------
(Millions of Dollars) 1998 1997 Amount Percent
- --------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Consumer $ 6,526 6,498 28 0.4%
Pharmaceutical 8,562 7,696 866 11.3
Professional 8,569 8,435 134 1.6
------------------------------
Worldwide total $23,657 22,629 1,028 4.5%
==============================
</TABLE>
27
<PAGE> 5
Operating Profit by Segment of Business(2)
- --------------------------------------------------------------------------------
[GRAPHIC OMITTED]
- --------------------------------------------------------------------------------
Operating Profit
<TABLE>
<CAPTION>
Percent of Sales
-----------------
(Millions of Dollars) 1998 1998(1) 1997 1998 1997
- --------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Consumer $ 414 658 551 6.3% 8.5%
Pharmaceutical 3,016 3,081 2,567 35.2 33.4
Professional 941 1,409 1,543 11.0 18.3
-------------------------------
Worldwide total 4,371 5,148 4,661 18.5 20.6
Expenses not
allocated to
segments (102) (102) (85) (.4) (.4)
-------------------------------
Earnings before
taxes on income $ 4,269 5,046 4,576 18.0% 20.2%
===============================
</TABLE>
(1) 1998 results excluding Restructuring and In-Process Research and Development
charges. Excluding these charges, operating profit as a percent of sales by
segment was: Consumer 10.1%, Pharmaceutical 36.0%, and Professional 16.4%.
(2) Prior year restated to conform to 1998 presentation according to SFAS No.
131.
Consumer
The Consumer segment's principal products are personal care and hygienic
products, including oral and baby care products, first aid products,
nonprescription drugs, sanitary protection products and adult skin and hair care
products. Major brands include ACT Fluoride Rinse; BAND-AID Brand Adhesive
Bandages; CAREFREE Panty Shields; CLEAN & CLEAR skin care products; IMODIUM A-D,
an antidiarrheal; JOHNSON'S Baby line of products; JOHNSON'S pH5.5 skin and hair
care products; MONISTAT, a remedy for vaginal yeast infections; adult and
children's MOTRIN analgesic products; MYLANTA gastrointestinal products and
PEPCID AC Acid Controller from the Johnson & JohnsonoMerck Consumer
Pharmaceuticals Co.; NEUTROGENA skin and hair care products; NICOTROL smoking
cessation products; o.b. Tampons; PENATEN and NATUSAN baby care products; PIZ
BUIN and SUNDOWN sun care products; REACH toothbrushes; RoC skin care products;
SHOWER TO SHOWER personal care products; STAYFREE and SURE & NATURAL sanitary
protection products; and the broad family of TYLENOL acetaminophen products.
These products are marketed principally to the general public and distributed
both to wholesalers and directly to independent and chain retail outlets.
Consumer segment sales in 1998 were $6.53 billion, an increase of .4% over
1997. Domestic sales increased by 2.6% while international sales declined by
1.7%. International sales gains in local currency of 5.2% were offset by a
negative currency impact of 6.9%. Consumer sales were led by continued strength
in the skin care franchise that includes the NEUTROGENA, RoC and CLEAN & CLEAR
product lines, as well as strong performances from the adult and children's
MOTRIN line of analgesic products. During the fourth quarter, the Company
announced the signing of a definitive agreement to acquire the dermatological
skin care business of S.C. Johnson & Son, Inc., including the AVEENO brand
specialty soaps, bath, anti-itch and moisturizing cream and lotion products.
The 1998 special pre-tax charge for the Consumer segment was $244 million.
See Note 15 for detailed discussion on the Restructuring charges.
Consumer segment sales in 1997 were $6.50 billion, an increase of 2.1%
over 1996. Sales by domestic companies accounted for 49.9% of the total segment,
while international companies accounted for 50.1%. During 1997, the Company
announced a licensing agreement with Raisio Group of Finland for the North
American marketing rights (as well as a letter of intent for the worldwide
marketing rights) to a dietary ingredient, stanol ester, which is patented for
use in reducing cholesterol. The Company also established an alliance with
Takeda Chemical Industries in Japan for the sale and distribution of OTC
products beginning with several forms of TYLENOL brand acetaminophen products.
Consumer segment sales in 1996 were $6.36 billion, an increase of 9.1%
over 1995. Sales by domestic companies accounted for 49.7% of the total segment,
while international companies accounted for 50.3%. The sales growth was led by
the strong performance of TYLENOL brand products, despite heavy competition.
Pharmaceutical
The Pharmaceutical segment represents over 50% of operating profit for all
segments.
The Pharmaceutical segment's principal worldwide franchises are in the
allergy, anti-infective, antifungal, antianemia, central nervous system,
contraceptive, dermatology, gastrointestinal, and pain management fields. These
products are distributed both directly and through wholesalers for use by health
care professionals and the general public.
Prescription drugs include DURAGESIC (fentanyl transdermal system sold
abroad as DUROGESIC), a transdermal patch for chronic pain; EPREX (Epoetin alfa
sold in the U.S. as PROCRIT), a biotechnology derived version of the human
hormone erythropoietin that stimulates red blood cell production; ERGAMISOL
(levamisole hydrochloride), a colon cancer drug; FLOXIN (ofloxacin) and LEVAQUIN
(levofloxacin), both anti-infectives; IMODIUM (loperamide HCl), an
antidiarrheal; LEUSTATIN (cladribine), for hairy cell leukemia; MOTILIUM
(domperidone), a gastrointestinal mobilizer; NIZORAL (ketoconazole), SPORANOX
(itraconazole) and TERAZOL (terconazole), antifungals; ORTHOCLONE OKT-3
(muromonab-CD3), for reversing the rejection of kidney, heart and liver
transplants; ORTHO-NOVUM (norethindrone/mestranol) group of oral contraceptives;
PREPULSID (cisapride sold in the U.S. as PROPULSID), a gastrointestinal
prokinetic; RETIN-A (tretinoin), a dermatological
28
<PAGE> 6
cream for acne; RISPERDAL (risperidone), an antipsychotic drug; and ULTRAM
(tramadol hydrochloride), a centrally acting prescription analgesic for moderate
to moderately severe pain.
Johnson & Johnson markets more than 90 prescription drugs around the
world, with 45% of the sales generated outside the United States. Twenty-eight
drugs sold by the Company had 1998 sales in excess of $50 million, with 17 of
them in excess of $100 million.
Pharmaceutical segment sales in 1998 were $8.56 billion, an increase of
11.3% over 1997 including 21.4% growth in domestic sales. International sales
increased .9% as sales gains in local currency of 5.7% were offset by a negative
currency impact of 4.8%. Worldwide growth reflects the strong performance of
RISPERDAL, PROCRIT, DURAGESIC, LEVAQUIN, and the oral contraceptive line of
products. At year-end 1998, the Company received approval from the FDA for
LEVAQUIN for the indication of uncomplicated urinary tract infection.
The 1998 special pre-tax charge for the Pharmaceutical segment was $65
million. See Note 15 for detailed discussion on the Restructuring charges.
Pharmaceutical segment sales in 1997 were $7.70 billion, an increase of
7.1% over 1996. This growth reflected the strong performance of RISPERDAL,
PROCRIT, PROPULSID, ULTRAM, DURAGESIC, and LEVAQUIN, a new anti-infective
launched in 1997. At year-end 1997, the Company received approval from the FDA
for REGRANEX (becaplermin), the first biologic treatment proven to increase the
incidence of healing in diabetic foot ulcers.
Pharmaceutical segment sales in 1996 were $7.19 billion, an increase of
14.6% over 1995. Domestic sales advanced 24.4% while international sales
advanced 7.2%. The worldwide growth was a result of the outstanding performances
of PROCRIT, RISPERDAL, SPORANOX, PROPULSID, ULTRAM, and DURAGESIC.
Significant research activities continued in the Pharmaceutical segment,
increasing to $1.4 billion in 1998, or $68 million over 1997. This represents
15.8% of 1998 Pharmaceutical sales and a compound annual growth rate of
approximately 14.6% for the five-year period since 1993.
Pharmaceutical research is led by two worldwide organizations, Janssen
Research Foundation, headquartered in Belgium and the R.W. Johnson
Pharmaceutical Research Institute, headquartered in the United States.
Additional research is conducted through collaboration with the James Black
Foundation in London, England.
Professional
The Professional segment includes suture and mechanical wound closure products,
minimally invasive surgical instruments, diagnostic products, cardiology
products, disposable contact lenses, surgical instruments, orthopaedic joint
replacements, products for wound management and infection prevention and other
medical equipment and devices. These products are used principally in the
professional fields by physicians, nurses, therapists, hospitals, diagnostic
laboratories and clinics. Distribution to these markets is done both directly
and through surgical supply and other dealers.
Worldwide sales of $8.57 billion in the Professional segment represented
an increase of 1.6% over 1997. Domestic sales decreased 2.4% while international
sales gains in local currency of 10.7% were partially offset by the strength of
the U.S. dollar.
Strong sales growth from Ethicon Endo-Surgery's laparoscopy and mechanical
closure products, Ethicon's Mitek suture anchors and Gynecare's women's health
products and the acquisition of the DePuy orthopaedic products business were
offset by a decline in sales of Cordis' coronary stents.
During the fourth quarter, the Company completed the acquisition of DePuy,
one of the world's leading orthopaedic products companies with products in
reconstructive, spinal, trauma and sports medicine for $3.7 billion. The Company
also completed the acquisition of FemRx, a leader in the development of
proprietary surgical systems that enable surgeons to perform less invasive
alternatives to hysterectomy.
At year-end 1998, two new Cordis products were approved for marketing by
the FDA. The S.M.A.R.T. stent, a self-expanding, crush-recoverable nitinol stent
was approved for use in treating biliary obstructions. Its nitinol alloy design
allows for precise placement and flexibility in reaching lesions, even through
very tortuous vessels. In addition, the NINJA balloon was approved in the U.S.
for use in angioplasty procedures.
The 1998 special pre-tax charge for the Professional segment for
restructuring was $304 million. Additionally, the write-off of IPR&D related to
acquisitions was $164 million. See Note 15 and 17 for detailed discussion on
Restructuring charges and Acquisitions.
Worldwide sales of $8.44 billion in 1997 in the Professional segment
represented an increase of 4.5 % over 1996. Sales growth continued to be fueled
by the excellent performance of Ethicon Endo-Surgery's minimally invasive
surgical instruments, Johnson & Johnson's orthopaedics business, Vistakon's
disposable contact lenses and LifeScan's blood glucose monitoring systems. The
Asia-Pacific and Central Europe regions contributed significantly to the overall
increase in the Professional segment. There were also several business
combinations in the Professional segment during 1997. These included Biopsys
Medical, Inc., a maker of products for the diagnosis and management of breast
cancer; Biosense, Inc., a leader in medical sensor technology for use in
diagnostic and therapeutic interventional procedures; Gynecare, Inc., a maker of
minimally invasive medical devices for the treatment of uterine disorders; and
Innotech, Inc., a manufacturer of equipment for high quality prescription
eyeglass lenses.
In 1996, Professional segment sales increased 19.8% over 1995, to $8.07
billion. The sales growth included the full year impact of the merger with
Cordis Corporation in early 1996. Strong growth in the Asia-Pacific region also
contributed to the increase in the Professional segment, as did excellent
performances by LifeScan's blood glucose monitors, Vistakon's disposable contact
lenses, Ethicon Endo-Surgery's minimally invasive surgical instruments and
Johnson & Johnson Professional's orthopaedic business. Acquisitions and
divestitures during 1998 and 1997 are described in more detail on page 42.
29
<PAGE> 7
Geographic Areas
The Company further categorizes its sales by major geographic area as presented
for the years 1998 and 1997.
Sales
<TABLE>
<CAPTION>
Increase
--------------------
(Millions of Dollars) 1998 1997 Amount Percent
- --------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
United States $12,562 11,757 805 6.8%
Europe 6,317 5,942 375 6.3
Western Hemisphere
excluding U.S. 2,090 2,034 56 2.8
Asia-Pacific, Africa 2,688 2,896 (208) (7.2)
-------------------------------
Worldwide total $23,657 22,629 1,028 4.5%
===============================
</TABLE>
International sales were once again negatively impacted by the translation of
local currency operating results into U.S. dollars. Average exchange rates to
the dollar have declined each year since 1995.
See page 45 for additional information on geographic areas.
Sales by Geographic Area of Business
- --------------------------------------------------------------------------------
[GRAPHIC OMITTED]
- --------------------------------------------------------------------------------
Description of Business
The Company, which employees 93,100 employees worldwide, is engaged in the
manufacture and sale of a broad range of products in the health care field. It
conducts business in virtually all countries of the world. The Company's primary
interest, both historically and currently, has been in products related to
health and well-being.
The Company is organized on the principle of decentralized management. The
Executive Committee of Johnson & Johnson is the principal management group
responsible for the operations and allocations of resources of the Company. In
addition, several Executive Committee members serve as Chairmen of Group
Operating Committees, which are comprised of managers who represent key
operations within the group, as well as management expertise in other
specialized functions. The composition of these Committees can change over time
in response to business needs. These Committees oversee and coordinate the
activities of domestic and international companies related to each of the
Consumer, Pharmaceutical and Professional businesses. Operating management is
headed by a Chairman, President, General Manager or Managing Director who
reports directly, or through a line executive to a Group Operating Committee.
In line with this policy of decentralization, each international
subsidiary is, with some exceptions, managed by citizens of the country where it
is located. The Company's international business is conducted by subsidiaries
manufacturing in 36 countries outside the United States and selling in over 175
countries throughout the world.
In all its product lines, the Company competes with companies both large
and small, located in the U.S. and abroad. Competition is strong in all lines
without regard to the number and size of the competing companies involved.
Competition in research, involving the development and improvement of new and
existing products and processes, is particularly significant and results from
time to time in product and process obsolescence. The development of new and
improved products is important to the Company's success in all areas of its
business. This competitive environment requires substantial investments in
continuing research and in multiple sales forces. In addition, the winning and
retention of customer acceptance of the Company's consumer products involves
heavy expenditures for advertising, promotion, and selling.
Cautionary Factors that May Affect Future Results
This Annual Report may contain forward-looking statements that anticipate
results based on management's plans that are subject to uncertainty. The use of
the words "expects," "plans, " "anticipates" and other similar words in
conjunction with discussions of future operations or financial performance
identifies these statements.
Forward-looking statements are based on current expectations of future
events. The Company cannot ensure that any forward-looking statement will be
accurate, although the Company believes that it has been reasonable in its
expectations and assumptions. Investors should realize that if underlying
assumptions prove inaccurate or that unknown risks or uncertainties materialize,
actual results could vary materially from our projections. The Company assumes
no obligation to update any forward-looking statements as a result of future
events or developments.
In Item 1 of the Company's Annual Report on Form 10-K for the year ended
January 3, 1999 that will be filed in April 1999, the Company discusses in more
detail various factors that could cause actual results to differ from
expectations. Prior to the filing of Form 10-K, investors should reference the
Company's quarterly report on Form 10-Q for the quarter ended September 27,
1998. The Company notes these factors as permitted by the Private Securities
Litigation Reform Act of 1995. Investors are cautioned not to place undue
reliance on such statements that speak only as of the date made. Investors also
should understand that it is not possible to predict or identify all such
factors and should not consider this list to be a complete statement of all
potential risks and uncertainties.
30
<PAGE> 8
Consolidated Balance Sheet Johnson & Johnson and Subsidiaries
<TABLE>
<CAPTION>
At January 3, 1999 and December 28, 1997 (Dollars in Millions) (Note 1) 1998 1997
- -----------------------------------------------------------------------------------------------
Assets
- -----------------------------------------------------------------------------------------------
<S> <C> <C>
Current assets
Cash and cash equivalents (Notes 1 and 16) $ 1,927 2,753
Marketable securities at cost (Note 16) 651 146
Accounts receivable trade, less allowances $385 (1997, $358) 3,661 3,329
Inventories (Notes 1 and 2) 2,853 2,516
Deferred taxes on income (Note 6) 1,180 831
Prepaid expenses and other receivables 860 988
--------------------
Total current assets $ 11,132 10,563
====================
Marketable securities, non-current (Note 16) 416 385
Property, plant and equipment, net (Notes 1, 3 and 15) 6,240 5,810
Intangible assets, net (Notes 1 and 5) 7,209 3,261
Deferred taxes on income (Note 6) 102 332
Other assets 1,112 1,102
--------------------
Total assets $ 26,211 21,453
====================
Liabilities and Shareowners' Equity
- -----------------------------------------------------------------------------------------------
Current liabilities
Loans and notes payable (Note 4) $ 2,747 714
Accounts payable 1,861 1,753
Accrued liabilities 2,920 2,258
Accrued salaries, wages and commissions 428 332
Taxes on income 206 226
--------------------
Total current liabilities 8,162 5,283
====================
Long-term debt (Note 4) 1,269 1,126
Deferred tax liability (Note 6) 578 175
Employee related obligations (Note 11) 1,738 1,562
Other liabilities 874 948
Shareowners' equity
Preferred stock-without par value
(authorized and unissued 2,000,000 shares) -- --
Common stock-par value $1.00 per share (Note 20)
(authorized 2,160,000,000 shares; issued 1,534,824,000 shares) 1,535 1,535
Note receivable from employee stock ownership plan (Note 14) (44) (51)
Accumulated other comprehensive income (Note 8) (328) (378)
Retained earnings 13,928 12,661
--------------------
15,091 13,767
Less common stock held in treasury, at cost (Note 20)
(190,773,000 and 189,687,000 shares) 1,501 1,408
--------------------
Total shareowners' equity 13,590 12,359
====================
Total liabilities and shareowners' equity $ 26,211 21,453
====================
</TABLE>
See Notes to Consolidated Financial Statements
31
<PAGE> 9
Consolidated Statement of Earnings Johnson & Johnson and Subsidiaries
<TABLE>
<CAPTION>
(Dollars in Millions Except Per Share Figures) (Note 1) 1998 1997 1996
- -----------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Sales to customers $ 23,657 22,629 21,620
================================
Cost of products sold (1998 includes $60 of inventory write-offs for restructuring) 7,496 7,152 7,018
--------------------------------
Gross profit 16,161 15,477 14,602
Selling, marketing and administrative expenses 8,907 8,715 8,394
Research expense 2,269 2,140 1,905
Purchased in-process research and development (Notes 15 and 17) 164 -- --
Interest income (262) (203) (139)
Interest expense, net of portion capitalized (Note 3) 110 120 125
Other expense, net 151 129 284
Restructuring charge (Note 15) 553 -- --
--------------------------------
11,892 10,901 10,569
--------------------------------
Earnings before provision for taxes on income 4,269 4,576 4,033
Provision for taxes on income (Note 6) 1,210 1,273 1,146
--------------------------------
Net earnings $ 3,059 3,303 2,887
================================
Basic net earnings per share (Notes 1 and 19) $ 2.27 2.47 2.17
================================
Diluted net earnings per share (Notes 1 and 19) $ 2.23 2.41 2.12
================================
</TABLE>
See Notes to Consolidated Financial Statements
32
<PAGE> 10
Consolidated Statement of Equity Johnson & Johnson and Subsidiaries
<TABLE>
<CAPTION>
Note Receivable Accumulated
From Employee Other Common
Comprehensive Retained Stock Ownership Comprehensive Stock Issued Treasury Stock
(Dollars in Millions) Total Income Earnings Plan (ESOP) Income Amount Amount
- -----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C>
Balance, December 31, 1995 $ 9,045 9,702 (64) 189 1,535 2,317
Net earnings 2,887 2,887 2,887
Cash dividends paid (974) (974)
Employee compensation and
stock option plans 204 (185) (389)
Repurchase of common stock (412) 412
Business combinations 318 (490) (808)
Other comprehensive income,
net of tax:
Currency translation adjustments (270) (270)
Unrealized gains on securities 31 31
-------
Other comprehensive income (239) (239)
-------
Total comprehensive income 2,648
=======
Note receivable from ESOP 7 7
------------------ -------------------------------------------------------------------------
Balance, December 29, 1996 $ 10,836 10,940 (57) (50) 1,535 1,532
================================================================================================
Net earnings 3,303 3,303 3,303
Cash dividends paid (1,137) (1,137)
Employee compensation and
stock option plans 290 (333) (623)
Repurchase of common stock (628) 628
Business combinations 17 (112) (129)
Other comprehensive income,
net of tax:
Currency translation adjustments (289) (289)
Unrealized gains (losses) on
securities (39) (39)
-------
Other comprehensive income (328) (328)
-------
Total comprehensive income 2,975
=======
Note receivable from ESOP 6 6
------------------ -------------------------------------------------------------------------
Balance, December 28, 1997 $ 12,359 12,661 (51) (378) 1,535 1,408
================================================================================================
Net earnings 3,059 3,059 3,059
Cash dividends paid (1,305) (1,305)
Employee compensation and
stock option plans 340 (494) (834)
Repurchase of common stock (930) 930
Business combinations 10 7 (3)
Other comprehensive income,
net of tax:
Currency translation adjustments 82 82
Unrealized gains (losses) on
securities (32) (32)
-------
Other comprehensive income 50 50
-------
Total comprehensive income 3,109
=======
Note receivable from ESOP 7 7
------------------ -------------------------------------------------------------------------
Balance, January 3, 1999 $ 13,590 13,928 (44) (328) 1,535 1,501
================================================================================================
</TABLE>
See Notes to Consolidated Financial Statements
33
<PAGE> 11
Consolidated Statement of Cash Flows Johnson & Johnson and Subsidiaries
<TABLE>
<CAPTION>
(Dollars in Millions) (Note 1) 1998 1997 1996
- ----------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Cash flows from operating activities
Net earnings $ 3,059 3,303 2,887
Adjustments to reconcile net earnings to cash flows:
Depreciation and amortization of property and intangibles 1,246 1,067 1,009
Increase in deferred taxes (239) (121) (3)
Purchased in-process research and development 164 -- --
Changes in assets and liabilities, net of effects from acquisition of businesses:
Increase in accounts receivable, less allowances (74) (318) (306)
Increase in inventories (80) (175) (242)
Increase in accounts payable and accrued liabilities 622 460 245
Decrease (increase) in other current and non-current assets 139 10 (40)
Increase in other current and non-current liabilities 49 117 341
-------------------------------
Net cash flows from operating activities 4,886 4,343 3,891
===============================
Cash flows from investing activities
Additions to property, plant and equipment (1,460) (1,391) (1,373)
Proceeds from the disposal of assets 71 69 37
Acquisition of businesses, net of cash acquired (Note 17) (3,481) (180) (233)
Other, principally marketable securities (769) (112) (123)
-------------------------------
Net cash used by investing activities (5,639) (1,614) (1,692)
===============================
Cash flows from financing activities
Dividends to shareowners (1,305) (1,137) (974)
Repurchase of common stock (930) (628) (412)
Proceeds from short-term debt 2,424 300 282
Retirement of short-term debt (226) (182) (128)
Proceeds from long-term debt 86 7 126
Retirement of long-term debt (416) (504) (411)
Proceeds from the exercise of stock options 269 225 149
-------------------------------
Net cash used by financing activities (98) (1,919) (1,368)
===============================
Effect of exchange rate changes on cash and cash equivalents 25 (68) (21)
-------------------------------
(Decrease) increase in cash and cash equivalents (826) 742 810
Cash and cash equivalents, beginning of year (Note 1) 2,753 2,011 1,201
-------------------------------
Cash and cash equivalents, end of year (Note 1) $ 1,927 2,753 2,011
===============================
- ----------------------------------------------------------------------------------------------------------------------
Supplemental cash flow data
Cash paid during the year for:
Interest, net of portion capitalized $ 89 91 113
Income taxes 1,310 1,431 1,210
Supplemental schedule of noncash investing and financing activities
Treasury stock issued for employee compensation and stock option plans
net of cash proceeds $ 598 425 252
Acquisitions of businesses
Fair value of assets acquired $ 4,322 184 237
Fair value of liabilities assumed (including $296 of assumed debt) (545) (4) (4)
-------------------------------
Net purchase price $ 3,777 180 233
===============================
</TABLE>
See Notes to Consolidated Financial Statements
34
<PAGE> 12
Notes to Consolidated Financial Statements Johnson & Johnson and Subsidiaries
- --------------------------------------------------------------------------------
1 Summary of Significant Accounting Policies
Principles of Consolidation
The consolidated financial statements include the accounts of Johnson & Johnson
and subsidiaries. Intercompany accounts and transactions are eliminated.
Cash Equivalents
The Company considers securities with maturities of three months or less, when
purchased, to be cash equivalents.
Revenue Recognition
The Company recognizes revenue from product sales when the goods are shipped and
title passes to the customer.
Inventories
Inventories are stated at the lower of cost or market determined by the
first-in, first-out method.
Depreciation of Property
The Company utilizes the straight-line method of depreciation for financial
statement purposes for all additions to property, plant and equipment.
Intangible Assets
The excess of the cost over the fair value of net assets of purchased businesses
is recorded as goodwill and is amortized on a straight-line basis over periods
of 40 years or less. The cost of other acquired intangibles is amortized on a
straight-line basis over their estimated useful lives. The Company continually
evaluates the carrying value of goodwill and other intangible assets. Any
impairments would be recognized when the expected future operating cash flows
derived from such intangible assets is less than their carrying value.
Financial Instruments
Gains and losses on foreign currency hedges of existing assets or liabilities,
or hedges of firm commitments, are deferred and recognized in income as part of
the related transaction.
Unrealized gains and losses on currency swaps which hedge third party debt
are classified in the balance sheet as other assets or liabilities. Interest
expense under these agreements, and the respective debt instruments that they
hedge, are recorded at the net effective interest rate of the hedged
transaction.
In the event of early termination of a currency swap contract that hedges
third party debt, the gain or loss on the swap contract is amortized over the
remaining life of the related transaction. If the underlying transaction
associated with a swap, or other derivative contract, is accounted for as a
hedge and is terminated early, the related derivative contract is terminated
simultaneously and any gains or losses would be included in income immediately.
Advertising
Costs associated with advertising are expensed in the year in- curred.
Advertising expenses worldwide, which are comprised of television, radio and
print media, were $1.19 billion in 1998 and $1.26 billion in 1997 and 1996
respectively.
Income Taxes
The Company intends to continue to reinvest its undistributed international
earnings to expand its international operations; therefore, no tax has been
provided to cover the repatriation of such undistributed earnings. At January 3,
1999 and December 28, 1997 the cumulative amount of undistributed international
earnings was approximately $7.0 billion and $5.9 billion, respectively.
Net Earnings Per Share
Basic earnings per share is computed by dividing net income available to common
shareowners by the weighted average number of common shares outstanding for the
period. Diluted earnings per share reflects the potential dilution that could
occur if securities or other contracts to issue common stock were exercised or
converted into common stock.
Risks and Uncertainties
The preparation of consolidated financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the amounts reported. Actual results are not
expected to differ materially from those estimates.
Annual Closing Date
The Company follows the concept of a fiscal year which ends on the Sunday
nearest to the end of the month of December. Normally each fiscal year consists
of 52 weeks, but every five or six years, as in 1998, the fiscal year consists
of 53 weeks.
Reclassification
Certain prior year amounts have been reclassified to conform with current year
presentation.
- --------------------------------------------------------------------------------
2 Inventories
At the end of 1998 and 1997, inventories were comprised of:
<TABLE>
<CAPTION>
(Dollars in Millions) 1998 1997
- --------------------------------------------------------------------------------
<S> <C> <C>
Raw materials and supplies $ 770 655
Goods in process 489 417
Finished goods 1,594 1,444
------------------------
$2,853 2,516
========================
</TABLE>
35
<PAGE> 13
- --------------------------------------------------------------------------------
3 Property, Plant and Equipment
At the end of 1998 and 1997, property, plant and equipment at cost and
accumulated depreciation consisted of:
<TABLE>
<CAPTION>
(Dollars in Millions) 1998 1997
- --------------------------------------------------------------------------------
<S> <C> <C>
Land and land improvements $ 459 407
Buildings and building equipment 2,922 2,895
Machinery and equipment 5,575 5,224
Construction in progress 1,068 918
-----------------------
10,024 9,444
Less accumulated depreciation 3,784 3,634
-----------------------
$ 6,240 5,810
=======================
</TABLE>
The Company capitalizes interest expense as part of the cost of
construction of facilities and equipment. Interest expense capitalized in 1998,
1997 and 1996 was $71, $40 and $55 million, respectively.
Upon retirement or other disposal of fixed assets, the cost and related
amount of accumulated depreciation or amortization are eliminated from the asset
and reserve accounts, respectively. The difference, if any, between the net
asset value and the proceeds is adjusted to income. For additional discussion on
property, plant and equipment, see Note 15.
- --------------------------------------------------------------------------------
4 Borrowings
The Components of long-term debt are as follows:
<TABLE>
<CAPTION>
Eff. Eff.
(Dollars in Millions) 1998 Rate 1997 Rate
- --------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
8.72% Debentures due 2024 $ 300 8.72% 300 8.72%
6.73% Debentures due 2023 250 6.73 250 6.73
7 3/8% Notes due 2002 199 7.49 199 7.49
8.25% Euro Notes
due 2004 199 8.37 199 8.37
11 1/4% Italian Lire Notes
due 1998(1) -- -- 115 4.88
5% Deutsche Mark Notes
due 2001(3) 107 1.98 101 1.98
5.12% Notes due 2003(4) 60 0.82 -- --
4 1/2% Currency Indexed
Notes due 1998(1) -- -- 72 5.26
8.18% to 8.25% Medium Term
Notes due 1998 -- -- 65 8.23
Industrial Revenue Bonds 50 5.28 57 5.77
Other, principally international 139 -- 36 --
------ -----
1,304 6.85(2) 1,394 6.96(2)
Less current portion 35 268
------ -----
$1,269 1,126
====== =====
</TABLE>
(1) The principal amounts of these debt issues include the effect of foreign
currency movements. Such debt was converted to fixed or floating rate U.S.
dollar liabilities via interest rate and currency swaps. Unrealized currency
gains (losses) on currency swaps are not included in the basis of the related
debt transactions and are classified in the balance sheet as other assets
(liabilities).
(2) Weighted average effective rate.
(3) Represents 5% Deutsche Mark notes due 2001 issued by a Japanese subsidiary
and converted to a 1.98% fixed rate yen note via an interest rate and currency
swap.
(4) Represents 5.12% U.S. Dollar notes due 2003 issued by a Japanese subsidiary
and converted to a 0.82% fixed rate yen note via an interest rate and currency
swap
.
The Company has access to substantial sources of funds at numerous banks
worldwide. Total unused credit available to the Company approximates $3.2
billion, including $1.2 billion of credit commitments with various worldwide
banks, $800 million of which expire on October 1, 1999 and $400 million on
October 6, 2003. Interest charged on borrowings under the credit line agreements
is based on either bids provided by the banks, the prime rate or London
Interbank Offered Rates (LIBOR), plus applicable margins. Commitment fees under
the agreements are not material.
The Company's shelf registration filed with the Securities and Exchange
Commission enables the Company to issue up to $2.59 billion of unsecured debt
securities, and warrants to purchase debt securities, under its medium term note
(MTN) program. No MTN's were issued during 1998. At January 3, 1999, the Company
had $2.29 billion remaining on its shelf registration. In 1998 the Company
issued $60 million of 5.12% notes due 2003, the proceeds of which were used for
general corporate purposes.
Short-term borrowings and current portion of long-term debt amounted to
$2.7 billion at the end of 1998. These borrowings are composed of $2.2 billion
U.S. commercial paper, at an average rate of 5.0% and $0.5 billion of local
borrowings, principally by international subsidiaries.
Aggregate maturities of long-term obligations for each of the next five
years commencing in 1999 are:
<TABLE>
<CAPTION>
After
(Dollars in Millions) 1999 2000 2001 2002 2003 2003
- --------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
$ 35 31 137 214 80 807
- --------------------------------------------------------------------------------
</TABLE>
5 Intangible Assets
At the end of 1998 and 1997, the gross and net amounts of intangible assets
were:
<TABLE>
<CAPTION>
(Dollars in Millions) 1998 1997
- --------------------------------------------------------------------------------
<S> <C> <C>
Goodwill - gross $4,112 2,198
Less accumulated amortization 329 241
-----------------------
Goodwill - net $3,783 1,957
=======================
Patents & trademarks - gross $1,634 1,074
Less accumulated amortization 343 262
-----------------------
Patents and trademarks - net $1,291 812
=======================
Other intangibles - gross $2,296 613
Less accumulated amortization 161 121
-----------------------
Other intangibles - net $2,135 492
=======================
Total intangible assets - gross $8,042 3,885
Less accumulated amortization 833 624
-----------------------
Total intangible assets - net $7,209 3,261
=======================
</TABLE>
The weighted average amortization periods for goodwill, patents and trademarks
and other intangibles are 32 years, 21 years and 18 years, respectively.
36
<PAGE> 14
- --------------------------------------------------------------------------------
6 Income Taxes
The provision for taxes on income consists of:
<TABLE>
<CAPTION>
(Dollars in Millions) 1998 1997 1996
- -------------------------------------------------------------------------------
<S> <C> <C> <C>
Currently payable:
U.S. taxes $ 964 939 662
International taxes 485 455 487
-----------------------------------------
1,449 1,394 1,149
-----------------------------------------
Deferred:
U.S. taxes (122) (115) 28
International taxes (117) (6) (31)
-----------------------------------------
(239) (121) (3)
-----------------------------------------
$ 1,210 1,273 1,146
=========================================
</TABLE>
Deferred income taxes are recognized for tax consequences of "temporary
differences" by applying enacted statutory tax rates, applicable to future
years, to differences between the financial reporting and the tax basis of
existing assets and liabilities.
Temporary differences and carryforwards for 1998 are as follows:
<TABLE>
<CAPTION>
Deferred Tax
----------------------
(Dollars in Millions) Asset Liability
- -------------------------------------------------------------------------------
<S> <C>
Employee benefit obligations $ 546 --
Depreciation -- (329)
Non-deductible intangibles -- (851)
International R&D capitalized for tax 150 --
Reserves & liabilities 609 --
Income reported for tax purposes 231 --
Miscellaneous international 168 (276)
Miscellaneous U.S. 377 --
-------------------------
Total deferred income taxes $2,081 (1,456)
========================
</TABLE>
A comparison of income tax expense at the federal statutory rate of 35% in
1998, 1997 and 1996, to the Company's effective tax rate is as follows:
<TABLE>
<CAPTION>
(Dollars in Millions) 1998 1997 1996
- ------------------------------------------------------------------------------
<S> <C> <C> <C>
Earnings before taxes
on income $4,269 4,576 4,033
----------------------------------------
Statutory taxes $1,494 1,602 1,412
Tax rates:
Statutory 35.0% 35.0% 35.0%
Puerto Rico & Ireland
operations (5.5) (5.7) (6.3)
Research tax credits (0.3) (0.3) (0.3)
Domestic state and local 1.0 1.0 1.6
International subsidiaries
excluding Ireland (3.3) (2.7) (2.0)
IPR&D 1.3 -- --
All other 0.1 0.5 0.4
----------------------------------------
Effective tax rate 28.3% 27.8% 28.4%
========================================
</TABLE>
The increase in the 1998 worldwide effective tax rate was primarily due to the
Company's fourth quarter purchased IPR&D charge. During 1998, the Company had
subsidiaries operating in Puerto Rico under a tax incentive grant expiring
December 31, 2007. In addition, the Company has subsidiaries manufacturing in
Ireland under an incentive tax rate effective through the year 2010.
- --------------------------------------------------------------------------------
7 International Currency Translation
For translation of its international currencies, the Company has determined that
the local currencies of its international subsidiaries are the functional
currencies except those in highly inflationary economies, which are defined as
those which have had compound cumulative rates of inflation of 100% or more
during the past three years.
In consolidating international subsidiaries, balance sheet currency
effects are recorded as a separate component of shareowners' equity. This equity
account includes the results of translating all balance sheet assets and
liabilities at current exchange rates, except for those located in highly
inflationary economies, principally Latin America, which are reflected in
operating results.
An analysis of the changes during 1998 and 1997 for cumulative currency
translation adjustments is included in Note 8.
Net currency transaction and translation gains and losses included in
other expense were after-tax losses of $15 million in 1998, after-tax losses of
$27 million in 1997, and after-tax gains of $2 million in 1996.
- --------------------------------------------------------------------------------
8 Accumulated Other Comprehensive Income
In June 1997, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 130 "Reporting Comprehensive Income" that the
Company adopted in the first quarter of 1998. SFAS 130 requires presentation of
comprehensive income and its components in the financial statements. Components
of other comprehensive income/(loss) consist of the following:
<TABLE>
<CAPTION>
Accumulated
Foreign Unrealized Other
Currency Gains/(Losses) Comprehensive
(Dollars in Millions) Translation on Securities Income/(Loss)
- -------------------------------------------------------------------------------
<S> <C> <C> <C>
December 31, 1995 $ 148 41 189
1996 change (270) 31 (239)
------------------------------------------
December 29, 1996 (122) 72 (50)
1997 change (289) (39) (328)
------------------------------------------
December 28, 1997 (411) 33 (378)
1998 change 82 (32) 50
------------------------------------------
January 3, 1999 $(329) 1 (328)
==========================================
</TABLE>
The change in unrealized gains/(losses) on marketable securities during 1998
includes reclassification adjustments of $38 million of losses realized from the
write-down of marketable securities and the associated tax benefit was $13
million. The tax effect on the components of other comprehensive income are
benefits of $17 million and $21 million in 1998 and 1997, respectively and
expense of $16 million in 1996 related to unrealized gains (losses) on
securities.
The currency translation adjustments are not adjusted for income taxes as
they relate to indefinite investments in non-U.S. subsidiaries.
37
<PAGE> 15
- --------------------------------------------------------------------------------
9 Rental Expense and Lease Commitments
Rentals of space, vehicles, manufacturing equipment and office and data
processing equipment under operating leases amounted to approximately $239
million in 1998, $235 million in 1997 and $237 million in 1996.
The approximate minimum rental payments required under operating leases that
have initial or remaining noncancellable lease terms in excess of one year at
January 3, 1999 are:
<TABLE>
<CAPTION>
After
(Dollars in Millions) 1999 2000 2001 2002 2003 2003 Total
- --------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C>
$80 64 45 37 31 78 335
</TABLE>
Commitments under capital leases are not significant.
- --------------------------------------------------------------------------------
10 Common Stock, Stock Option Plans and Stock
Compensation Agreements
At January 3, 1999 the Company had eight stock-based compensation plans. Under
the 1995 Employee Stock Option Plan, the Company may grant options to its
employees for up to 56 million shares of common stock. The shares outstanding
are for contracts under the Company's 1986, 1991 and 1995 Employee Stock Option
Plans, the 1997 Non-Employee Directors' Plan and the Mitek, Cordis, Biosense and
Gynecare Stock Option plans.
Stock options expire ten years from the date they are granted and vest
over service periods that range from one to six years. Shares available for
future grants amounted to 15.0 million, 22.7 million and 32.9 million in 1998,
1997 and 1996, respectively.
A summary of the status of the Company's stock option plans as of January
3, 1999, December 28, 1997 and December 29, 1996 and changes during the years
ending on those dates, is presented below:
<TABLE>
<CAPTION>
Options Weighted Average
(Shares in Thousands) Outstanding* Exercise Price
- --------------------------------------------------------------------------------
<S> <C> <C>
Balance at December 31, 1995 78,624 24.89
Options granted 10,120 43.81
Options exercised (7,442) 16.13
Options cancelled/forfeited (2,231) 29.27
-----------------------------
Balance at December 29, 1996 79,071 28.01
Options granted 12,564 60.62
Options exercised (10,597) 16.80
Options cancelled/forfeited (2,193) 36.36
-----------------------------
Balance at December 28, 1997 78,845 34.48
Options granted 9,872 80.05
Options exercised (11,076) 18.59
Options cancelled/forfeited (2,204) 44.46
-----------------------------
Balance at January 3, 1999 75,437 42.49
=============================
</TABLE>
* Adjusted to reflect the 1996 two-for-one stock split.
The Company applies the provisions of Financial Accounting Standards No.
123, "Accounting for Stock-Based Compensation," that calls for companies to
measure employee stock compensation expense based on the fair value method of
accounting. However, as allowed by the Statement, the Company elected continued
use of Accounting Principle Board (APB) Opinion No. 25, "Accounting for Stock
Issued to Employees, " with pro forma disclosure of net income and earnings per
share determined as if the fair value method had been applied in measuring
compensation cost. Had the fair value method been applied, net income would have
been reduced by $66 million or $.05 per share in 1998 and $30 million or $.02
per share in 1997. In 1996, net income would have been reduced by $16 million or
$.01 earnings per share. These calculations only take into account the options
issued since January 1, 1995. The average fair value of options granted was
$19.62 in 1998, $17.50 in 1997 and $13.37 in 1996. The fair value was estimated
using the Black-Scholes option pricing model based on the weighted average
assumptions of:
<TABLE>
<CAPTION>
1998 1997 1996
- --------------------------------------------------------------------------------
<S> <C> <C> <C>
Risk-free rate 4.52% 5.89% 6.11%
Volatility 22.0% 21.5% 18.2%
Expected life 5 yrs 5.3 yrs 7 yrs
Dividend yield 1.30% 1.43% 1.48%
</TABLE>
The following table summarizes stock options outstanding and exercisable
at January 3, 1999:
<TABLE>
<CAPTION>
(Shares in Thousands) Outstanding Exercisable
- ------------------------------------------------------------ -----------------
Average Average
Exercise Average Exercise Exercise
Price Range Options Life(a) Price Options Price
- ------------------------------------------------------------ -----------------
<S> <C> <C> <C> <C> <C>
$8.00-$22.28 11,973 3.2 $18.78 10,629 $18.39
$22.32-$42.86 22,733 4.7 24.93 18,016 24.61
$43.13-$59.88 20,477 7.2 46.44 7,238 44.97
$60.13-$83.63 20,254 9.4 72.19 1 71.06
------------------------------ -----------------
$8.00-$83.63 75,437 6.4 $42.49 35,884 $26.88
============================== =================
</TABLE>
(a) Average contractual life remaining in years
- --------------------------------------------------------------------------------
11 Employee Related Obligations
At the end of 1998 and 1997, employee related obligations were:
<TABLE>
<CAPTION>
(Dollars in Millions) 1998 1997
- --------------------------------------------------------------------------------
<S> <C> <C>
Post retirement benefits $ 767 753
Post employment benefits 144 166
Unfunded pension liabilities 677 517
Certificates of extra compensation 150 126
-----------------------
Employee related obligations $1,738 1,562
=======================
</TABLE>
- --------------------------------------------------------------------------------
12 Segments of Business and Geographic Areas
In 1998 the Company adopted Financial Accounting Standards No. 131, "Segments of
Business;" see page 45.
38
<PAGE> 16
- --------------------------------------------------------------------------------
13 Retirement and Pension Plans
The Company sponsors various retirement and pension plans, including defined
benefit, defined contribution and termination indemnity plans, which cover most
employees worldwide. The Company also provides postretirement benefits,
primarily health care to all domestic retired employees and their dependents.
Most international employees are covered by government-sponsored programs and
the cost to the Company is not significant.
Retirement plan benefits are primarily based on the employee's
compensation during the last three to five years before retirement and the
number of years of service. The Company's objective in funding its domestic
plans is to accumulate funds sufficient to provide for all accrued benefits.
International subsidiaries have plans under which funds are deposited with
trustees, annuities are purchased under group contracts, or reserves are
provided.
In certain countries other than the United States, the funding of pension
plans is not a common practice as funding provides no economic benefit.
Consequently, the Company has several pension plans which are not funded.
The Company does not fund retiree health care benefits in advance and has
the right to modify these plans in the future.
Effective December 29, 1997, the Company adopted Statement of Financial
Accounting Standards (SFAS) No. 132,"Employers' Disclosures about Pensions and
Postretirement Benefits," which standardizes the disclosure requirements for
pensions and other postretirement benefits. The Statement addresses disclosure
only. It does not address liability measurement or expense recognition. There
was no effect on financial position or net income as a result of adopting SFAS
No. 132.
Net periodic benefit costs for the Company's defined benefit retirement
plans and other benefit plans for 1998, 1997 and 1996 include the following
components:
<TABLE>
<CAPTION>
Retirement Plans Other Benefit Plans
- -------------------------------------------------------------------------------------------------
(Dollars in Millions) 1998 1997 1996 1998 1997 1996
- -------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Service cost $ 185 166 159 20 17 16
Interest cost 254 239 230 50 46 46
Expected return on plan assets (291) (256) (231) (14) (3) (3)
Amortization of prior service cost 17 16 14 2 1 1
Amortization of net transition assets (14) (13) (13) -- -- --
Recognized actuarial (gain)/loss (24) (19) 2 8 (6) (1)
Curtailments and settlements 2 1 -- -- -- --
---------------------------------------------------------
Net periodic benefit cost $ 129 134 161 66 55 59
=========================================================
</TABLE>
The net periodic cost attributable to domestic retirement plans included above
was $40 million in 1998, $50 million in 1997 and $84 million in 1996.
The following tables provide the weighted-average assumptions used to
develop net periodic benefit cost and the actuarial present value of projected
benefit obligations:
<TABLE>
<CAPTION>
Retirement Plans Other Benefit Plans
- -----------------------------------------------------------------------------------------------------------------------------
Domestic Benefit Plans 1998 1997 1996 1998 1997 1996
- -----------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Weighted average discount rate 6.75% 7.25% 7.75% 6.75% 7.25% 7.75%
Expected long-term rate of return on plan assets 9.0 9.0 9.0 9.0 9.0 9.0
Rate of increase in compensation levels 5.0 5.0 5.5 5.0 5.0 5.5
International Benefit Plans
- -----------------------------------------------------------------------------------------------------------------------------
Weighted average discount rate 5.50% 6.25% 6.50% 6.00% 7.00% 7.25%
Expected long-term rate of return on plan assets 7.75 7.75 7.75 -- -- --
Rate of increase in compensation levels 3.50 4.25 4.75 4.25 5.00 5.00
</TABLE>
Health care cost trends are projected at annual rates grading from 10% for
employees under age 65 and 7% for employees over age 65 down to 5% for both
groups by the year 2008 and beyond. The effect of a 1% change in these assumed
cost trends on the accumulated postretirement benefit obligation at the end of
1998 would be a $99 million increase or an $88 million decrease and the effect
on the service and interest cost components of the net periodic postretirement
benefit cost for 1998 would be a $12 million increase or a $10 million decrease.
39
<PAGE> 17
The following tables set forth the change in benefit obligations and
change in plan assets at year-end 1998 and 1997 for the Company's defined
benefit retirement plans and other postretirement plans:
<TABLE>
<CAPTION>
(Dollars in Millions) Retirement Plans Other Benefit Plans
- -----------------------------------------------------------------------------------------------------------
Change in Benefit Obligation 1998 1997 1998 1997
- -----------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Benefit obligation - beginning of year $3,704 3,412 691 591
Service cost 185 166 20 17
Interest cost 254 239 50 46
Plan participant contributions 11 10 -- --
Amendments 13 27 -- --
Actuarial loss 325 123 -- 66
Curtailments & settlements (7) 1 -- --
Total benefits paid (203) (175) (33) (28)
Effect of exchange rates 33 (99) (2) (1)
------------------------------------------
Benefit obligation - end of year $4,315 3,704 726 691
==========================================
<CAPTION>
Change in Plan Assets
- -----------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Plan assets at fair value - beginning of year $3,694 3,330 46 41
Actual return on plan assets 606 547 14 8
Company contributions 45 35 29 24
Plan participant contributions 11 10 -- --
Settlements (4) -- -- --
Benefits paid from plan assets (193) (158) (32) (27)
Effect of exchange rates 14 (70) -- --
------------------------------------------
Plan assets at fair value - end of year $4,173 3,694 57 46
==========================================
</TABLE>
Amounts recognized in the Company's balance sheet consist of the following:
<TABLE>
<CAPTION>
Retirement Plans Other Benefit Plans
- -----------------------------------------------------------------------------------------------------------
(Dollars in Millions) 1998 1997 1998 1997
- -----------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Plan assets less than projected benefit obligation $ (142) (10) (668) (645)
Unrecognized actuarial gains (511) (543) (117) (107)
Unrecognized prior service cost 98 102 (11) (8)
Unrecognized net transition asset (37) (51) -- --
------------------------------------------
Total recognized in the consolidated balance sheet $ (592) (502) (796) (760)
==========================================
Book reserves $ (726) (592) (796) (760)
Prepaid benefits 109 75 -- --
Intangible assets 25 15 -- --
------------------------------------------
Total recognized in the consolidated balance sheet $ (592) (502) (796) (760)
==========================================
</TABLE>
Plans with accumulated benefit obligations in excess of plan assets consist of
the following:
<TABLE>
<CAPTION>
Retirement Plans Other Benefit Plans
- -----------------------------------------------------------------------------------------------------------
(Dollars in Millions) 1998 1997 1998 1997
- -----------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Accumulated benefit obligation $ (558) (435) (696) (691)
Projected benefit obligation $ (723) (566) -- --
Plan assets at fair value $ 162 126 57 46
</TABLE>
40
<PAGE> 18
- --------------------------------------------------------------------------------
14 Savings Plan
The Company has voluntary 401(k) savings plans designed to enhance the existing
retirement programs covering eligible employees. The Company matches a
percentage of each employee's contributions consistent with the provisions of
the plan for which he/she is eligible.
In the U.S. salaried plan, one-third of the Company match is paid in
Company stock under an employee stock ownership plan (ESOP). In 1990, to
establish the ESOP, the Company loaned $100 million to the ESOP Trust to
purchase shares of the Company stock on the open market. In exchange, the
Company received a note, the balance of which is recorded as a reduction of
shareowners' equity.
Total Company contributions to the plans were $63 million in 1998, $58
million in 1997, and $50 million in 1996.
- --------------------------------------------------------------------------------
15 Restructuring and In-Process Research and Development Charges
In the fourth quarter of 1998, the Company approved a plan to reconfigure its
global network of manufacturing and operating facilities with the objective of
enhancing operating efficiencies. It is expected that the plan will be completed
over the next eighteen months. Among the initiatives supporting this plan were
the closure of inefficient manufacturing facilities, exiting certain businesses
which were not providing an acceptable return and related employee separations.
The closure of these facilities represented approximately 10% of the Company's
manufacturing capacity.
The estimated cost of this plan is $613 million which has been reflected
in cost of sales ($60 million) and restructuring charge ($553 million). The
charge consisted of employee separation costs of $161 million, asset impairments
of $322 million, impairments of intangibles of $52 million, and other exit costs
of $78 million. Employee separations will occur primarily in manufacturing and
operations facilities affected by the plan. The decision to exit certain
facilities and businesses decreased cash flows triggering the asset impairment.
The amount of impairment of such assets was calculated using discounted cash
flows or appraisals.
Special charges recorded during 1998 were as follows:
<TABLE>
<CAPTION>
Beginning 1998 Remaining
(Dollars in Millions) Accrual Cash Outlays Accrual
- --------------------------------------------------------------------------------
<S> <C> <C> <C>
Restructuring charges:
Employee separations $161 3 158
Other exit costs 78 -- 78
------------------------------------
239 3 236
------------------------------------
Asset impairments 322
Intangible assets 52
---------
Total restructuring plan 613
In-process R&D 164
---------
Total special charges $777
=========
</TABLE>
The headcount reduction for the year ended January 3, 1999 was
approximately 225 employees.
In connection with the businesses acquired in 1998, the Company recognized
charges for in-process research and development (IPR&D) in the amount of $164
million related primarily to DePuy. The value of the IPR&D projects was
calculated with the assistance of third party appraisers and was based on the
estimated percentage completion of the various research and development projects
being pursued using cash flow projections discounted for the risk inherent in
such projects. The majority of the value of the IPR&D is associated with DePuy
projects that focus on spinal and hip implants. For additional discussion on
acquisitions, see Note 17.
The special charges impacted the business segments as follows: the special
pre-tax charge for the Consumer segment was $244 million. This charge reflects
$85 million for severance costs associated with the termination of approximately
2,550 employees; $133 million for the write-down of impaired assets and $26
million for other exit costs. The Pharmaceutical business segment recorded $65
million of the special charge representing $18 million for severance costs
associated with the termination of approximately 250 employees and $47 million
for the write-down of impaired assets. Acquisitions within the Professional
business segment resulted in a $164 million write-off of purchased IPR&D.
Additionally, the Professional business segment recorded other special charges
of $304 million. This charge included $58 million for severance costs associated
with the termination of approximately 2,300 employees; $194 million for the
write-down of impaired assets and $52 million for other exit costs.
- --------------------------------------------------------------------------------
16 Financial Instruments
Derivative Financial Instrument Risk
The Company uses derivative financial instruments to manage the impact of
interest rate and foreign exchange rate changes on earnings and cash flows. The
Company does not enter into financial instruments for trading or speculative
purposes.
The Company has a policy of only entering into contracts with parties that
have at least an "A" (or equivalent) credit rating. The counterparties to these
contracts are major financial institutions and the Company does not have
significant exposure to any one counterparty. Management believes the risk of
loss is remote and in any event would be immaterial.
Interest Rate and Foreign Exchange Risk Management
The Company uses interest rate and currency swaps to manage interest rate and
currency risk primarily related to borrowings. Interest rate and currency swap
agreements that hedge third party debt mature with these borrowings and are
described in Note 4.
The Company enters into forward foreign exchange contracts maturing within
five years to protect the value of existing foreign currency assets and
liabilities and to hedge future foreign currency product costs. The Company has
forward exchange contracts outstanding at year-end in various currencies,
principally in U.S. Dollars, Belgian Francs and Swiss Francs. In addition, the
Company has currency swaps outstanding, principally in U.S. Dollars, Belgian
Francs and French Francs. Unrealized gains and losses, based on dealer quoted
market prices, are presented in the following table:
<TABLE>
<CAPTION>
1998
-------------------------------------
Notional
(Dollars in Millions) Amounts Gains Losses
- --------------------------------------------------------------------------------
<S> <C> <C> <C>
Forwards $6,848 94 227
Currency swaps 3,422 25 89
</TABLE>
41
<PAGE> 19
Fair Value of Financial Instruments
The carrying amount of cash and cash equivalents and current and non-current
marketable securities approximates fair value of these instruments. In addition
the carrying amount of long-term investments, long-term debt, interest rate and
currency swaps (used to hedge third party debt) approximates fair value of these
instruments for 1998 and 1997.
The fair value of current and non-current marketable securities, long-term
debt and interest rate and currency swap agreements was estimated based on
quotes obtained from brokers for those or similar instruments. The fair value of
long-term investments was estimated based on quoted market prices at year-end.
Concentration of Credit Risk
The Company invests its excess cash in both deposits with major banks throughout
the world and other high quality short-term liquid money market instruments
(commercial paper, government and government agency notes and bills, etc.). The
Company has a policy of making investments only with commercial institutions
that have at least an "A" (or equivalent) credit rating. These investments
generally mature within six months and the Company has not incurred any related
losses.
The Company sells a broad range of products in the health care field in
most countries of the world. Concentrations of credit risk with respect to trade
receivables are limited due to the large number of customers comprising the
Company's customer base. Ongoing credit evaluations of customers' financial
condition are performed and, generally, no collateral is required. The Company
maintains reserves for potential credit losses and such losses, in the
aggregate, have not exceeded management's expectations.
- --------------------------------------------------------------------------------
17 Mergers, Acquisitions and Divestitures
Certain businesses were acquired for $3.8 billion during 1998 and the purchase
method of accounting was employed. The most significant 1998 acquisition was
DePuy, Inc., a leading orthopaedics company. DePuy's product lines include
reconstructive products (implants for hips, knees and extremities), spinal
implants, trauma repair and sports-related injury products.
The excess of purchase price over the estimated fair value amounted to
$3.3 billion. This amount has been allocated to identifiable intangibles and
goodwill. Approximately $164 million has been identified as the value of IPR&D
associated with the acquisitions. The majority of the value is associated with
DePuy projects that focus on spinal and hip implants, which were near regulatory
approval as of the acquisition date. The remaining effort and cost to complete
these projects is not expected to be material. The Company is in the process of
finalizing a plan to reconfigure and integrate DePuy's operations, which will be
completed within one year of acquisition. This effort is expected to result in
employee terminations, facility closures and other related costs, which will be
recorded as adjustments to the opening balance sheet and are not expected to be
material. Pro forma information is not provided since the impact of the
acquisitions does not have a material effect on the Company's results of
operations, cash flows or financial position.
During 1997, certain businesses were merged with Johnson & Johnson at a
value, net of cash, of $737 million. The mergers have been accounted for as
poolings of interests; prior period financial statements have not been restated
since the effect of these mergers would not materially effect previously issued
financial statements. The 1997 mergers included Biopsys Medical, Inc., Biosense,
Inc. and Gynecare, Inc. Biopsys Medical, Inc. is an innovator and marketer of
the MAMMOTOME Breast Biopsy System. Biosense, Inc. is a leader in developing
medical sensor technology and is developing several applications that will
facilitate a variety of diagnostic and therapeutic interventional and
cardiovascular procedures. Gynecare, Inc. is the developer and marketer of
innovative, minimally invasive medical devices utilized in the treatment of
uterine disorders.
Certain businesses were acquired for $180 million during 1997 and the
purchase method of accounting was employed. The most significant 1997
acquisition was Innotech, Inc., a developer and marketer of eyeglass lens
products.
The excess of purchase price over the estimated fair value of 1997
acquisitions amounted to $157 million. This amount has been allocated to
identifiable intangibles and goodwill. Pro forma information is not provided for
in 1997 as the impact of the acquisition does not have a material effect on the
Company's results of operations, cash flows or financial position.
Divestitures in 1998 and 1997 did not have a material effect on the
Company's results of operations, cash flows or financial position.
- --------------------------------------------------------------------------------
18 Pending Legal Proceedings
The Company is involved in numerous product liability cases in the United
States, many of which concern adverse reactions to drugs and medical devices.
The damages claimed are substantial, and while the Company is confident of the
adequacy of the warnings which accompany such products, it is not feasible to
predict the ultimate outcome of litigation. However, the Company believes that
if any liability results from such cases, it will be substantially covered by
reserves established under its self-insurance program and by commercially
available excess liability insurance.
The Company, along with numerous other pharmaceutical manufacturers and
distributors, is a defendant in a large number of individual and class actions
brought by retail pharmacies in state and federal courts under the antitrust
laws. These cases assert price discrimination and price-fixing violations
resulting from an alleged industry-wide agreement to deny retail pharmacists
price discounts on sales of brand name prescription drugs. The Company believes
the claims against the Company in these actions are without merit and is
defending them vigorously.
The Company, together with another contact lens manufacturer, a trade
association and various individual defendants, is a defendant in several
consumer class actions and an action brought by multiple State Attorneys General
on behalf of consumers alleging violations of federal and state antitrust laws.
These cases assert that enforcement of the Company's long-standing policy of
selling contact lenses only to licensed eye care professionals is a result of an
unlawful conspiracy to eliminate alternative distribution channels from the
disposable contact lens market. The Company believes that these actions are
without merit and is defending them vigorously.
The Company is involved in a number of patent, trademark and other
lawsuits incidental to its business. Among those is a patent infringement action
in which U.S. Surgical Corporation seeks substantial damages and an injunction
based on what it alleges are infringing trocar surgical instrument sales by the
Company's Ethicon Endo-Surgery unit. The Company disputes infringement as well
as the validity and enforceability of the asserted patents and is vigorously
contesting the claims.
42
<PAGE> 20
However, it is not possible to predict with certainty the outcome of litigation,
and while the Company does not believe an adverse result would have a material
effect on the Company's consolidated financial position, it could be material to
the results of operations for a fiscal year.
The Company's Ortho Biotech subsidiary is party to an arbitration
proceeding filed against it by Amgen, Ortho's licensor of U.S. non-dialysis
rights to EPO, in which Amgen seeks to terminate Ortho's U.S. license rights
based on alleged deliberate EPO sales by Ortho during the early 1990's into
Amgen's reserved dialysis market. The Company believes no basis exists for
terminating Ortho's U.S. license rights and is vigorously contesting Amgen's
claims. However, Ortho's U.S. license rights to EPO are material to the Company;
thus, an unfavorable outcome could have a material adverse effect on the
Company's consolidated financial position, liquidity or results of operations.
In December 1998, Ortho Biotech was found in a separate arbitration not to
have rights in what Amgen describes as its second-generation EPO product, known
as Novel Erythropoiesis Stimulating Protein, or NESP. The effect of the ruling
is to allow Amgen's NESP product, if approved, to compete with Ortho's EPO
product in the U.S. non-dialysis market and in all markets overseas, except
China and Japan, which are reserved to Kirin-Amgen. Currently, Ortho is Amgen's
exclusive licensee for EPO in U.S. non-dialysis markets and in all ex-U.S.
markets except China and Japan. Because NESP is still in clinical trials, it is
not possible to predict the impact on Ortho's marketing of EPO.
The Company believes that the above proceedings, except as noted above,
would not have a material adverse effect on its results of operations, cash
flows or financial position.
- --------------------------------------------------------------------------------
19 Earnings Per Share
The following is a reconciliation of basic net earnings per share to diluted net
earnings per share for the years ended January 3, 1999, December 28, 1997 and
December 29, 1996:
<TABLE>
<CAPTION>
(Shares in Millions) 1998(1) 1997 1996
- -------------------------------------------------------------------------------
<S> <C> <C> <C>
Basic net earnings per share $ 2.27 2.47 2.17
Average shares outstanding
- basic 1,344.8 1,336.0 1,332.6
Potential shares exercisable
under stock option plans 65.8 68.1 71.6
Less: shares repurchased under
treasury stock method (39.0) (34.2) (44.8)
---------------------------------------
Adjusted average shares
outstanding - diluted 1,371.6 1,369.9 1,359.4
Diluted earnings per share $ 2.23 2.41 2.12
=======================================
</TABLE>
(1) 1998 results excluding Restructuring and In-Process Research & Development
charges are: Basic EPS at $2.73 and diluted EPS at $2.67 (unaudited).
- --------------------------------------------------------------------------------
20 Capital and Treasury Stock Changes in treasury stock were:
<TABLE>
<CAPTION>
Treasury Stock
Amounts in millions except number of shares in thousands Shares Amount
- -------------------------------------------------------------------------------
<S> <C> <C>
Balance at December 31, 1995 239,464 $2,317
Employee compensation and stock
option plans (8,510) (389)
Repurchase of common stock 8,745 412
Business combinations (37,359) (808)
------------------
Balance at December 29, 1996 202,340 1,532
Employee compensation and stock
option plans (11,175) (623)
Repurchase of common stock 10,520 628
Business combinations (11,998) (129)
------------------
Balance at December 28, 1997 189,687 1,408
Employee compensation and stock
option plans (11,516) (834)
Repurchase of common stock 12,602 930
Business combinations (3)
------------------
Balance at January 3, 1999 190,773 $1,501
==================
</TABLE>
Shares of common stock authorized and issued were 1,534,824,000 shares at the
end of 1998, 1997, 1996 and 1995.
- --------------------------------------------------------------------------------
21 Selected Quarterly Financial Data (Unaudited)
Selected unaudited quarterly financial data for the years 1998 and 1997 is
summarized below:
<TABLE>
<CAPTION>
1998 1997
------------------------------------------- ------------------------------------------
(Dollars in Millions First Second Third Fourth First Second Third Fourth
Except Per Share Figures) Quarter Quarter Quarter Quarter(1) Quarter Quarter Quarter Quarter
-----------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Segment sales to customers
Consumer $1,639 1,571 1,587 1,731 1,683 1,612 1,585 1,618
Pharmaceutical 2,092 2,162 2,098 2,210 1,944 1,934 1,918 1,900
Professional 2,052 2,050 2,039 2,426 2,088 2,152 2,083 2,112
-----------------------------------------------------------------------------------------
Total sales 5,783 5,783 5,724 6,367 5,715 5,698 5,586 5,630
=========================================================================================
Gross profit 4,006 3,980 3,966 4,209 3,943 3,949 3,836 3,749
Earnings before provision
for taxes on income 1,434 1,371 1,317 147 1,302 1,294 1,197 783
Net earnings 1,010 1,005 961 83 909 909 855 630
=========================================================================================
Basic net earnings per share $ 0.75 .75 .71 .06 .68 .68 .64 .47
=========================================================================================
Diluted net earnings per share $ 0.73 .74 .70 .06 .66 .67 .63 .45
=========================================================================================
</TABLE>
(1) 1998 results excluding Restructuring and In-Process Research & Development
charges: Earnings before taxes $924; Net earnings $693; Basic EPS $.52 and
Diluted EPS $.50.
43
<PAGE> 21
Report of Management
The management of Johnson & Johnson is responsible for the integrity and
objectivity of the accompanying financial statements and related information.
The statements have been prepared in conformity with generally accepted
accounting principles, and include amounts that are based on our best judgments
with due consideration given to materiality.
Management maintains a system of internal accounting controls monitored by
a corporate staff of professionally trained internal auditors who travel
worldwide. This system is designed to provide reasonable assurance, at
reasonable cost, that assets are safeguarded and that transactions and events
are recorded properly. While the Company is organized on the principle of
decentralized management, appropriate control measures are also evidenced by
well-defined organizational responsibilities, management selection, development
and evaluation processes, communicative techniques, financial planning and
reporting systems and formalized procedures.
It has always been the policy and practice of the Company to conduct its
affairs ethically and in a socially responsible manner. This responsibility is
characterized and reflected in the Company's Credo and Policy on Business
Conduct that are distributed throughout the Company. Management maintains a
systematic program to ensure compliance with these policies.
PricewaterhouseCoopers LLP, independent auditors, is engaged to audit our
financial statements. Pricewaterhouse-Coopers LLP maintains an understanding of
our internal controls and conducts such tests and other auditing procedures
considered necessary in the circumstances to express their opinion in the report
that follows.
The Audit Committee of the Board of Directors, composed solely of outside
directors, meets periodically with the independent auditors, management and
internal auditors to review their work and confirm that they are properly
discharging their responsibilities. In addition, the independent auditors, the
General Counsel and the Vice President, Internal Audit are free to meet with the
Audit Committee without the presence of management to discuss the results of
their work and observations on the adequacy of internal financial controls, the
quality of financial reporting and other relevant matters.
/s/ Ralph S. Larsen /s/ Robert J. Darretta
Ralph S. Larsen Robert J. Darretta
Chairman, Board of Directors Vice President, Finance
and Chief Executive Officer and Chief Financial Officer
Independent Auditor's Report
To the Shareowners and Board of Directors of Johnson & Johnson:
In our opinion, the accompanying consolidated balance sheets and the related
consolidated statements of earnings, consolidated statements of equity, and
consolidated statements of cash flows present fairly, in all material respects,
the financial position of Johnson & Johnson and its subsidiaries at January 3,
1999 and December 28, 1997, and the results of their operations and their cash
flows for each of the three years in the period ended January 3, 1999, in
conformity with generally accepted accounting principles. These financial
statements are the responsibility of the Company's management; our
responsibility is to express an opinion on these financial statements based on
our audits. We conducted our audits of these statements in accordance with
generally accepted auditing standards which require that we plan and perform the
audit to obtain reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements,
assessing the accounting principles used and significant estimates made by
management, and evaluating the overall financial statement presentation. We
believe that our audits provide a reasonable basis for the opinion expressed
above.
/s/ PricewaterhouseCooper LLP
New York, New York
January 25, 1999
44
<PAGE> 22
Segments of Business(1) Johnson & Johnson and Subsidiaries
<TABLE>
<CAPTION>
Sales to Customers(2)
-----------------------------
(Dollars in Millions) 1998 1997 1996
- ----------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Consumer-Domestic $ 3,325 3,240 3,166
International 3,201 3,258 3,198
-----------------------------
Total 6,526 6,498 6,364
-----------------------------
Pharmaceutical-Domestic 4,707 3,877 3,355
International 3,855 3,819 3,833
-----------------------------
Total 8,562 7,696 7,188
-----------------------------
Professional-Domestic 4,530 4,640 4,378
International 4,039 3,795 3,690
-----------------------------
Total 8,569 8,435 8,068
-----------------------------
Worldwide total $23,657 22,629 21,620
=============================
</TABLE>
<TABLE>
<CAPTION>
Operating Profit(3) Identifiable Assets
----------------------------- ----------------------------
(Dollars in Millions) 1998(5) 1997 1996 1998 1997 1996
- ----------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Consumer $ 414 551 346 4,645 4,745 4,874
Pharmaceutical 3,016 2,567 2,441 6,441 5,919 5,581
Professional 941 1,543 1,406 12,856 7,773 7,505
--------------------------------------------------------------
Segments total 4,371 4,661 4,193 23,942 18,437 17,960
Expenses not allocated to segments(4) (102) (85) (160)
General corporate 2,269 3,016 2,050
--------------------------------------------------------------
Worldwide total $ 4,269 4,576 4,033 26,211 21,453 20,010
==============================================================
</TABLE>
<TABLE>
<CAPTION>
Additions to Property, Depreciation and
Plant & Equipment Amortization
----------------------------- ----------------------------
(Dollars in Millions) 1998 1997 1996 1998 1997 1996
- ----------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Consumer $ 268 267 294 273 265 257
Pharmaceutical 515 460 445 313 267 265
Professional 627 573 594 629 495 446
--------------------------------------------------------------
Segments total 1,410 1,300 1,333 1,215 1,027 968
General corporate 50 91 40 31 40 41
--------------------------------------------------------------
Worldwide total $ 1,460 1,391 1,373 1,246 1,067 1,009
==============================================================
</TABLE>
Geographic Areas (2)
<TABLE>
<CAPTION>
Sales to Customers(2) Long-Lived Assets(3)
----------------------------- ----------------------------
(Dollars in Millions) 1998 1997 1996 1998 1997 1996
- ----------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
United States $12,562 11,757 10,899 8,284 5,623 5,200
Europe 6,317 5,942 6,151 4,072 2,357 2,452
Western Hemisphere excluding U.S. 2,090 2,034 1,914 429 457 441
Asia-Pacific, Africa 2,688 2,896 2,656 402 384 435
--------------------------------------------------------------
Segments total 23,657 22,629 21,620 13,187 8,821 8,528
General corporate 262 250 230
Other non long-lived assets 12,762 12,382 11,252
--------------------------------------------------------------
Worldwide total $23,657 22,629 21,620 26,211 21,453 20,010
==============================================================
</TABLE>
(1) See Management's Discussion and Analysis, pages 27 to 30, for a
description of the segments in which the Company does business.
(2) Export sales and intersegment sales are not significant. No single
customer or country represents 10% or more of total sales.
(3) Prior years restated to conform to 1998 presentation according to SFAS No.
131.
(4) Amounts not allocated to segments include interest income/expense,
minority interests and general corporate income and expense.
(5) 1998 results excluding Restructuring and In-Process Research and
Development charges: Consumer $658, Pharmaceutical $3,081 and Professional
$1,409.
See Note 15 for details of Restructuring and IPR&D charges by segment.
Geographic Areas(2)
45
<PAGE> 23
Summary of Operations and
Statistical Data 1988-1998 Johnson & Johnson and Subsidiaries
<TABLE>
<CAPTION>
(Dollars in Millions Except Per Share Figures) 1998 1997 1996 1995 1994 1993
- ----------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Sales to customers - Domestic $ 12,562 11,757 10,899 9,190 7,812 7,203
Sales to customers - International 11,095 10,872 10,721 9,652 7,922 6,935
-------------------------------------------------------------
Total sales 23,657 22,629 21,620 18,842 15,734 14,138
=============================================================
Cost of products sold 7,496 7,152 7,018 6,235 5,299 4,791
Selling, marketing and administrative expenses 8,907 8,715 8,394 7,462 6,350 5,771
Research expense 2,269 2,140 1,905 1,634 1,278 1,182
Purchased in-process research and development 164 -- -- -- -- --
Interest income (262) (203) (139) (115) (60) (80)
Interest expense, net of portion capitalized 110 120 125 143 142 126
Other expense (income), net 151 129 284 166 44 16
Restructuring charge 553 -- -- -- -- --
-------------------------------------------------------------
19,388 18,053 17,587 15,525 13,053 11,806
-------------------------------------------------------------
Earnings before provision for taxes on income 4,269 4,576 4,033 3,317 2,681 2,332
Provision for taxes on income 1,210 1,273 1,146 914 675 545
-------------------------------------------------------------
Earnings before cumulative effect of accounting changes 3,059 3,303 2,887 2,403 2,006 1,787
Cumulative effect of accounting changes (net of tax) -- -- -- -- -- --
-------------------------------------------------------------
Net earnings $ 3,059 3,303 2,887 2,403 2,006 1,787
=============================================================
Percent of sales to customers 12.9(3) 14.6 13.4 12.8 12.7 12.6
Basic net earnings per share of common stock* $ 2.27(3) 2.47 2.17 1.86 1.56 1.37
=============================================================
Diluted net earnings per share of common stock* $ 2.23(3) 2.41 2.12 1.82 1.55 1.36
=============================================================
Percent return on average shareowners' equity 23.6(3) 28.5 29.0 29.7 31.6 33.3
=============================================================
Percent increase (decrease) over previous year:
Sales to customers 4.5 4.7 14.7 19.8 11.3 2.8
Basic net earnings per share (8.1)(3) 13.8 16.7 19.2 13.9 75.6(1)
=============================================================
Diluted net earnings per share (7.5)(3) 13.7 16.5 17.4 14.0 76.6(1)
Supplementary expense data: =============================================================
Cost of materials and services(5) $ 11,580 11,484 11,204 9,852 7,952 7,033
Total employment costs 5,659 5,387 5,275 4,707 4,282 4,066
Depreciation and amortization 1,246 1,067 1,009 857 724 617
Maintenance and repairs(6) 294 265 281 252 217 202
Total tax expense(7) 1,845 1,843 1,699 1,433 1,142 968
Total tax expense per share(7)* 1.37 1.38 1.27 1.11 .89 .74
=============================================================
Supplementary balance sheet data:
Property, plant and equipment, net $ 6,240 5,810 5,651 5,196 4,910 4,406
Additions to property, plant and equipment 1,460 1,391 1,373 1,256 937 975
Total assets 26,211 21,453 20,010 17,873 15,668 12,242
Long-term debt 1,269 1,126 1,410 2,107 2,199 1,493
=============================================================
Common stock information:*
Dividends paid per share $ .97 .85 .735 .64 .565 .505
Shareowners' equity per share $ 10.11 9.19 8.13 6.98 5.54 4.33
Market price per share (year-end close) $ 83 7/8 64 7/8 50 1/2 42 3/4 27 3/8 22 3/8
Average shares outstanding (millions) - basic 1,344.8 1,336.0 1,332.6 1,291.9 1,286.1 1,303.5
- diluted 1,371.6 1,369.9 1,359.4 1,317.4 1,297.2 1,315.1
Shareowners of record (thousands) 165.9 156.8 138.5 113.5 104.7 96.1
=============================================================
Employees (thousands) 93.1 90.5 89.3 82.3 81.5 81.6
=============================================================
<CAPTION>
(Dollars in Millions Except Per Share Figures) 1992 1991 1990 1989 1988
- ---------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Sales to customers - Domestic 6,903 6,248 5,427 4,881 4,576
Sales to customers - International 6,850 6,199 5,805 4,876 4,424
------------------------------------------------------
Total sales 13,753 12,447 11,232 9,757 9,000
======================================================
Cost of products sold 4,678 4,204 3,937 3,480 3,292
Selling, marketing and administrative expenses 5,671 5,099 4,469 3,897 3,630
Research expense 1,127 980 834 719 674
Purchased in-process research and development -- -- -- -- --
Interest income (93) (88) (98) (87) (72)
Interest expense, net of portion capitalized 124 129 201(4) 141 104
Other expense (income), net 39 85 266(4) 93 (24)
Restructuring charge -- -- -- -- --
------------------------------------------------------
11,546 10,409 9,609 8,243 7,604
------------------------------------------------------
Earnings before provision for taxes on income 2,207 2,038 1,623 1,514 1,396
Provision for taxes on income 582 577 480 432 422
------------------------------------------------------
Earnings before cumulative effect of accounting changes 1,625 1,461 1,143 1,082 974
Cumulative effect of accounting changes (net of tax) (595) -- -- -- --
------------------------------------------------------
Net earnings 1,030 1,461 1,143 1,082 974
======================================================
Percent of sales to customers 7.5(1) 11.7 10.2(2) 11.1 10.8
Basic net earnings per share of common stock* .78 1.10 .86 .81 .71
======================================================
Diluted net earnings per share of common stock* .77 1.08 .85 .80 .70
======================================================
Percent return on average shareowners' equity 19.1(1) 27.8 25.3(2) 28.3 27.9
======================================================
Percent increase (decrease) over previous year:
Sales to customers 10.5 10.8 15.1 8.4 12.3
Basic net earnings per share (29.1)(1) 27.9(2) 6.2(2) 14.1 18.2
======================================================
Diluted net earnings per share (28.7)(1) 27.1(2) 6.3(2) 14.3 18.6
======================================================
Supplementary expense data:
Cost of materials and services(5) 6,857 6,329 5,728 4,908 4,528
Total employment costs 4,044 3,507 3,195 2,871 2,639
Depreciation and amortization 560 493 474 414 391
Maintenance and repairs(6) 210 203 185 193 191
Total tax expense(7) 1,000 966 825 708 678
Total tax expense per share(7)* .76 .73 .62 .53 .50
======================================================
Supplementary balance sheet data:
Property, plant and equipment, net 4,115 3,667 3,247 2,846 2,493
Additions to property, plant and equipment 1,103 987 830 750 664
Total assets 11,884 10,513 9,506 7,919 7,119
Long-term debt 1,365 1,301 1,316 1,170 1,166
======================================================
Common stock information:*
Dividends paid per share .445 .385 .33 .28 .24
Shareowners' equity per share 3.94 4.22 3.68 3.11 2.63
Market price per share (year-end close) 25 1/4 28 5/8 17 7/8 14 7/8 10 5/8
Average shares outstanding (millions) - basic 1,318.9 1,332.3 1,332.2 1,332.5 1,362.4
- diluted 1,336.9 1,353.2 1,349.7 1,350.8 1,379.6
Shareowners of record (thousands) 84.1 69.9 64.6 60.5 54.5
======================================================
Employees (thousands) 84.9 82.7 82.2 83.1 81.3
======================================================
</TABLE>
* Adjusted to reflect the 1996 two-for-one stock split.
(1) Excluding the cumulative effect of accounting changes of $595 million.-1992
earnings percent of sales to customers before accounting changes is 11.8%. -1992
earnings percent return on average shareowners' equity before accounting changes
is 28.5%. -1993 basic net earnings per share percent increase over prior year
before accounting change is 11.4%; 1992 is 12.3%.
(2) Excluding Latin America non-recurring charges of $125 million. -1990 net
earnings percent of sales to customers before non-recurring charges is
11.3%.-1990 percent return on average shareowners' equity before non-recurring
charges is 27.6%. -1991 basic net earnings per share percent increase over prior
year before non-recurring charges is 15.3%; 1990 is 17.3%.
(3) Excluding Restructuring and In-Process Research and Development charges of
$610 million. -1998 earnings percent of sales to customers before special
charges is 15.5%. -1998 basic net earnings per share before special charges of
$2.73. -1998 diluted net earnings per share before special charges is $2.67.
- -1998 percent return on average shareowners' equity before special charges is
27.6%. -1998 basic net earnings per share increase over prior year before
special charges is 10.5%. -1998 diluted net earnings per share increase over
prior year before special charges is 10.8%. - 1998 cost of products sold
includes $60 million of inventory write-offs for restructuring.
(4) Includes Latin America non-recurring charge of $36 million for the
liquidation of Argentine debt and $104 million writedown in other expenses for
permanent impairment of certain assets and operations in Latin America.
(5) Net of interest and other income.
(6) Also included in cost of materials and services category.
(7) Includes taxes on income, payroll, property and other business taxes.
46
<PAGE> 1
EXHIBIT 21
SUBSIDIARIES
Johnson & Johnson, a New Jersey corporation, has the domestic and
international subsidiaries shown below. Certain domestic subsidiaries and
international subsidiaries are not named because they are not significant in the
aggregate. Johnson & Johnson has no parent.
<TABLE>
<CAPTION>
JURISDICTION OF
NAME OF SUBSIDIARY ORGANIZATION
------------------ ---------------
<S> <C>
Domestic Subsidiaries:
Biopsys Medical, Inc. .................................... Delaware
Biosense, Inc............................................. Delaware
Cordis Corporation........................................ Florida
Cordis International Corporation.......................... Delaware
Cordis Webster, Inc. ..................................... California
DePuy, Inc................................................ Delaware
DePuy ACE Medical Co...................................... California
DePuy AcroMed, Inc. ...................................... Ohio
DePuy Finance LLC......................................... Delaware
DePuy Orthopaedics, Inc. ................................. Indiana
DePuy Orthopaedic Technologies, Inc. ..................... Delaware
Ethicon Endo-Surgery, Inc. ............................... Ohio
Ethicon, Inc. ............................................ New Jersey
Ethicon LLC............................................... Delaware
GynoPharma Inc. .......................................... Delaware
Indigo Medical, Incorporated ............................. Delaware
Janssen Ortho LLC......................................... Delaware
Janssen Pharmaceutica Inc. ............................... Pennsylvania
Janssen Products, Inc. ................................... Delaware
Johnson & Johnson Consumer Companies, Inc. ............... New Jersey
Johnson & Johnson Development Corporation................. New Jersey
Johnson & Johnson Finance Corporation..................... New Jersey
Johnson & Johnson Health Care Systems Inc. ............... New Jersey
Johnson & Johnson International........................... New Jersey
Johnson & Johnson Japan Inc. ............................. New Jersey
Johnson & Johnson - Merck Consumer Pharmaceuticals Co. ... New Jersey
Johnson & Johnson (Middle East) Inc. ..................... New Jersey
Johnson & Johnson Professional, Inc. ..................... New Jersey
Johnson & Johnson (Russia), Inc. ......................... New Jersey
Johnson & Johnson S.E., Inc............................... New Jersey
Johnson & Johnson Services, Inc. ......................... New Jersey
Johnson & Johnson Vision Products, Inc. .................. Florida
Joint Medical Products Corporation........................ Delaware
JJHC, Inc. ............................................... Delaware
LifeScan, Inc. ........................................... California
LifeScan LLC.............................................. Delaware
McNeil Consumer Brands, Inc............................... New Jersey
McNEIL-PPC, Inc. ......................................... New Jersey
NDC Investment Corporation................................ Delaware
</TABLE>
16
<PAGE> 2
<TABLE>
<CAPTION>
JURISDICTION OF
NAME OF SUBSIDIARY ORGANIZATION
------------------ ---------------
<S> <C>
Neutrogena Corporation.................................... Delaware
Nitinol Development Corporation........................... California
Noramco, Inc. ............................................ Georgia
OMJ Pharmaceuticals, Inc. ................................ Delaware
Ortho Biologics LLC....................................... Delaware
Ortho Biotech Inc. ....................................... New Jersey
Ortho-Clinical Diagnostics, Inc. ......................... New York
Ortho-McNeil Pharmaceutical, Inc. ........................ Delaware
Raritan Advertising, Inc. ................................ New Jersey
RoC USA Corporation....................................... Delaware
Therakos, Inc. ........................................... Florida
International Subsidiaries:
Abello Farmacia SL........................................ Italy
Bioland Pharma S.A.R.L. .................................. France
Centra Medicamenta OTC SRL................................ Italy
Cilag AG.................................................. Switzerland
Cilag AG International.................................... Switzerland
Cilag de Mexico, S.A. de C.V. ............................ Mexico
Cilag Farmaceutica Ltda. ................................. Brazil
Cilag Holding AG.......................................... Switzerland
Corange U.K. Holdings Ltd................................. United Kingdom
Cordis AB ................................................ Sweden
Cordis Europa N.V. ....................................... Netherlands
Cordis Medizinische Apparate GmbH ........................ Germany
Cordis S.A. .............................................. France
DePuy Australia Pty. Ltd.................................. Australia
DePuy Bioland S.A......................................... France
DePuy France S.A.......................................... France
DePuy International Ltd................................... United Kingdom
DePuy Intl. (Holdings) Ltd................................ United Kingdom
DePuy Japan Inc........................................... Japan
DePuy Orthopedie GmbH..................................... Germany
DePuy Orthopedie S.A...................................... France
Ethicon Endo-Surgery (Europe) GmbH ....................... Germany
Ethicon GmbH & Co. KG..................................... Germany
Ethicon Ireland Limited................................... Ireland
Ethicon Limited........................................... Scotland
Ethicon S.A.S............................................. France
Ethicon S.p.A. ........................................... Italy
Ethnor (Proprietary) Limited.............................. South Africa
Greiter AG................................................ Switzerland
Greiter Distribution AG................................... Switzerland
Greiter (International) AG................................ Switzerland
Janssen Animal Health BVBA................................ Belgium
Janssen-Cilag A/S......................................... Norway
Janssen-Cilag AB.......................................... Sweden
Janssen-Cilag AG.......................................... Switzerland
</TABLE>
17
<PAGE> 3
<TABLE>
<CAPTION>
JURISDICTION OF
NAME OF SUBSIDIARY ORGANIZATION
------------------ ---------------
<S> <C>
Janssen-Cilag A/S......................................... Denmark
Janssen-Cilag B.V. ....................................... Netherlands
Janssen-Cilag Egypt Ltd. ................................. Egypt
Janssen-Cilag C.A. ....................................... Venezuela
Janssen-Cilag Farmaceutica Ltda........................... Brazil
Janssen-Cilag Farmaceutica, Ltda. ........................ Portugal
Janssen-Cilag International N.V. ......................... Belgium
Janssen-Cilag Ltd......................................... United Kingdom
Janssen-Cilag Limited..................................... South Africa
Janssen-Cilag Medizinische Information GmbH............... Austria
Janssen-Cilag N.V. ....................................... Belgium
Janssen-Cilag OY.......................................... Finland
Janssen-Cilag Pharmaceutical S.A.C.I. .................... Greece
Janssen-Cilag Pharma Vertrieb GmbH........................ Austria
Janssen-Cilag Pty. Limited................................ Australia
Janssen-Cilag S.A. ....................................... Spain
Janssen-Cilag S.A. ....................................... France
Janssen-Cilag S.p.A. ..................................... Italy
Janssen Farmaceutica, S.A. de C.V. ....................... Mexico
Janssen-Cilag GmbH........................................ Germany
Janssen-Cilag International N.V........................... Belgium
Janssen International C.V. ............................... Belgium
Janssen Korea, Ltd. ...................................... Korea
Janssen-Kyowa Co., Ltd. .................................. Japan
Janssen Ortho Inc. ....................................... Canada
Janssen Pharmaceutica Limited............................. Thailand
Janssen Pharmaceutica N.V. ............................... Belgium
Janssen Pharmaceutical Limited............................ Ireland
J-C Healthcare Ltd. ...................................... Israel
JHC Nederland B.V. ....................................... Netherlands
J&J/MSD Consumer Pharmaceuticals S.A.S.................... France
Johnson & Johnson AB...................................... Sweden
Johnson & Johnson AG...................................... Switzerland
Johnson & Johnson A/S..................................... Denmark
Johnson & Johnson S.A. de C.V. ........................... Mexico
Johnson & Johnson de Argentina, S.A.C.e I. ............... Argentina
Johnson & Johnson (China) Ltd. ........................... China
Johnson & Johnson Consumer N.V./S.A....................... Belgium
Johnson & Johnson de Colombia S.A. ....................... Colombia
Johnson & Johnson del Ecuador S.A. ....................... Ecuador
Johnson & Johnson (Egypt) S.A.E........................... Egypt
Johnson & Johnson Finance Limited......................... United Kingdom
Johnson & Johnson/Gaba B.V. .............................. Netherlands
Johnson & Johnson GmbH.................................... Germany
Johnson & Johnson Gesellschaft m.b.H...................... Austria
Johnson & Johnson Hellas S.A. ............................ Greece
Johnson & Johnson (Holding) GmbH.......................... Germany
</TABLE>
18
<PAGE> 4
<TABLE>
<CAPTION>
JURISDICTION OF
NAME OF SUBSIDIARY ORGANIZATION
------------------ ---------------
<S> <C>
Johnson & Johnson (Hong Kong) Limited..................... Hong Kong
Johnson & Johnson Inc. ................................... Canada
Johnson & Johnson Industria e Comercio Ltda............... Brazil
Johnson & Johnson International S.A. ..................... France
Johnson & Johnson Investments Limited..................... United Kingdom
Johnson & Johnson (Ireland) Limited....................... Ireland
Johnson & Johnson (Kenya) Limited......................... Kenya
Johnson & Johnson Korea Ltd. ............................. Korea
Johnson & Johnson Kft. ................................... Hungary
Johnson & Johnson K.K. ................................... Japan
Johnson & Johnson Leasing GmbH............................ Germany
Johnson & Johnson Lda..................................... Portugal
Johnson & Johnson Ltd..................................... United Kingdom
Johnson & Johnson Ltd. ................................... India
Johnson & Johnson Management Ltd. ........................ United Kingdom
Johnson & Johnson Medical B.V. ........................... Netherlands
Johnson & Johnson Medical (China) Ltd. ................... China
Johnson & Johnson Medical G.m.b.H. ....................... Austria
Johnson & Johnson Medical GmbH............................ Germany
Johnson & Johnson Medical K.K. ........................... Japan
Johnson & Johnson Medical Korea Limited................... Korea
Johnson & Johnson Medical Limited. ....................... United Kingdom
Johnson & Johnson Medical Mfg. Sdn. Bhd. ................. Malaysia
Johnson & Johnson Medical NV/SA........................... Belgium
Johnson & Johnson Medical Pty. Ltd. ...................... Australia
Johnson & Johnson Medical S.A. ........................... Argentina
Johnson & Johnson Medical S.A.R.L. ....................... France
Johnson & Johnson Morocco S.A. ........................... Morocco
Johnson & Johnson (New Zealand) Limited................... New Zealand
Johnson & Johnson Pacific Pty. Ltd. ...................... Australia
Johnson & Johnson Pakistan (Private) Limited.............. Pakistan
Johnson & Johnson (Philippines), Inc. .................... Philippines
Johnson & Johnson Poland Sp. z o.o. ...................... Poland
Johnson & Johnson (Private) Limited....................... Zimbabwe
Johnson & Johnson Products Inc. .......................... Canada
Johnson & Johnson Produtos Profissionais Ltda............. Brazil
Johnson & Johnson Professional Products (Proprietary) South Africa
Ltd. ..................................................
Johnson & Johnson (Proprietary) Limited................... South Africa
Johnson & Johnson Pte. Ltd. .............................. Singapore
Johnson & Johnson Pty. Limited............................ Australia
Johnson & Johnson Research Pty. Limited................... Australia
Johnson & Johnson, S.A. de C.V. .......................... Mexico
Johnson & Johnson S.A.S. ................................. France
Johnson & Johnson S.A. ................................... Spain
Johnson & Johnson SDN. BHD. .............................. Malaysia
Johnson & Johnson S.p.A. ................................. Italy
Johnson & Johnson, Spol.s.r.o. ........................... Czech Republic
</TABLE>
19
<PAGE> 5
<TABLE>
<CAPTION>
JURISDICTION OF
NAME OF SUBSIDIARY ORGANIZATION
------------------ ---------------
<S> <C>
Johnson & Johnson Taiwan Ltd. ............................ Taiwan
Johnson & Johnson (Thailand) Ltd.......................... Thailand
Johnson & Johnson Vision Products AB...................... Sweden
Johnson & Johnson Vision Products (Ireland) Ltd........... Ireland
Johnson & Johnson (Zambia) Limited........................ Zambia
Laboratoires Martin Johnson & Johnson -- MSD S.A.S........ France
Laboratoires Polive S.N.C. ............................... France
Lifescan Canada Ltd. ..................................... Canada
Medos S.A. ............................................... Switzerland
Neutrogena Corporation S.A.R.L. .......................... France
Neutrogena Provence S.A.R.L............................... France
OMJ Ireland Limited....................................... Ireland
OMJ Manufacturing Ltd..................................... Ireland
Ortho-Clinical Diagnostics European Support Center........ France
Ortho-Clinical Diagnostics GmbH........................... Germany
Ortho-Clinical Diagnostics K.K. .......................... Japan
Ortho-Clinical Diagnostics................................ United Kingdom
Ortho-Clinical Diagnostics S.A. .......................... Spain
Ortho-Clinical Diagnostics N.V. .......................... Belgium
Ortho-Clinical Diagnostics S.A. .......................... France
Ortho-Clinical Diagnostics S.p.A. ........................ Italy
Pharma Argentina S.A. .................................... Argentina
P.T. Johnson & Johnson Indonesia.......................... Indonesia
RoC S.A.S. ............................................... France
The R.W. Johnson Pharmaceutical Research Institute........ Switzerland
Shanghai Johnson & Johnson Pharmaceuticals, Ltd........... China
Shanghai Johnson & Johnson Ltd. .......................... China
Surgikos, S.A. de C.V. ................................... Mexico
Tasmanian Alkaloids Pty. Ltd. ............................ Australia
Taxandria Pharmaceutica B.V. ............................. Netherlands
Vania Expansion, S.N.C.................................... France
Woelm Pharma GmbH & Co.................................... Germany
Xian-Janssen Pharmaceutical Limited....................... China
</TABLE>
20
<PAGE> 1
EXHIBIT 23
CONSENT OF INDEPENDENT AUDITORS
We consent to the incorporation by reference in Registration Statements No.
33-52252, 33-40294, 33-40295, 33-32875, 33-7634, 033-59009, 333-38055, 333-40681
and 333-26979 on Form S-8. No. 33-55977 and 33-47424 on Form S-3 and No.
33-57583, 333-00391, 333-38097 and 333-30081 on Form S-4 and related
Prospectuses of our reports dated January 25, 1999, on our audits of the
consolidated financial statements and financial statement schedule of Johnson &
Johnson and subsidiaries as of January 3, 1999 and December 28, 1997, and for
each of the three years in the period ended January 3, 1999, which reports are
included or incorporated by reference in this Annual Report on Form 10-K.
/s/ PricewaterhouseCoopers LLP
PRICEWATERHOUSECOOPERS LLP
New York, New York
March 30, 1999
21
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
1998 results excluding Restructuring and In-Process Research and Development
charges; Earnings before Taxes $5,046; Net Earnings $3,669; Basic EPS $2.73 and
Diluted EPS $2.67.
</LEGEND>
<MULTIPLIER> 1,000,000
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> JAN-03-1999
<PERIOD-END> JAN-03-1999
<CASH> 1,927
<SECURITIES> 651
<RECEIVABLES> 4,046
<ALLOWANCES> 385
<INVENTORY> 2,853
<CURRENT-ASSETS> 11,132
<PP&E> 10,024
<DEPRECIATION> 3,784
<TOTAL-ASSETS> 26,211
<CURRENT-LIABILITIES> 8,162
<BONDS> 1,304
0
0
<COMMON> 1,535
<OTHER-SE> 12,055
<TOTAL-LIABILITY-AND-EQUITY> 26,211
<SALES> 23,657
<TOTAL-REVENUES> 23,657
<CGS> 7,496
<TOTAL-COSTS> 7,496
<OTHER-EXPENSES> 2,269
<LOSS-PROVISION> 39
<INTEREST-EXPENSE> 110
<INCOME-PRETAX> 4,269
<INCOME-TAX> 1,210
<INCOME-CONTINUING> 3,059
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 3,059
<EPS-PRIMARY> 2.27
<EPS-DILUTED> 2.23
</TABLE>
<PAGE> 1
EXHIBIT 99(b)
CAUTIONARY STATEMENT PURSUANT TO PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995 -- "SAFE HARBOR" FOR FORWARD-LOOKING STATEMENTS
The Company may from time to time make certain forward-looking statements
in publicly-released materials, both written and oral. Forward-looking
statements do not relate strictly to historical or current facts and may be
identified by their use of words like "plans," "expects", "will", "anticipates,"
"estimates" and other words of similar meaning. Such statements may address,
among other things, the Company's strategy for growth, product development,
regulatory approvals, market position, expenditures, financial results and the
effect of Year 2000 readiness issues.
Forward-looking statements are based on current expectations of future
events. The Company cannot guarantee that expectations expressed in
forward-looking statements will be realized. Some important factors that could
cause the Company's actual results to differ materially from those projected in
any such forward-looking statements are as follows:
Economic factors, including inflation and fluctuations in interest
rates and foreign currency exchange rates and the potential effect of such
fluctuations on revenues, expenses and resulting margins;
Competitive factors, including technological advances achieved and
patents attained by competitors and generic competition as patents on the
Company's products expire;
Domestic and foreign healthcare changes resulting in pricing
pressures, including the continued consolidation among healthcare
providers, trends toward managed care and healthcare cost containment and
government laws and regulations relating to sales and promotion,
reimbursement and pricing generally;
Government laws and regulations, affecting domestic and foreign
operations, including those relating to trade, monetary and fiscal
policies, taxes, price controls, regulatory approval of new products and
licensing;
Difficulties inherent in product development, including the potential
inability to successfully continue technological innovation, complete
clinical trials, obtain regulatory approvals in the United States and
abroad, gain and maintain market approval of products and the possibility
of encountering infringement claims by competitors with respect to patent
or other intellectual property rights which can preclude or delay
commercialization of a product;
Significant litigation adverse to the Company including product
liability claims, patent infringement claims, and antitrust claims;
Product efficacy or safety concerns resulting in product recalls or
declining sales;
The impact of business combinations, including acquisitions and
divestitures, and organizational restructuring consistent with evolving
business strategies;
Issuance of new or revised accounting standards by the American
Institute of Certified Public Accountants, the Financial Accounting
Standards Board or the Securities and Exchange Commission;
The dates for completion of specified tasks in the Company's Year 2000
readiness program and the assessment of future costs are based upon, among
other things, assumptions of the lack of complicating factors that could
cause delay, the availability of adequate resources, including
appropriately skilled third parties, and the availability of substitute or
alternate products or services, where required;
The assessments of the Year 2000 readiness of others and of the
effects of lack of such readiness are highly uncertain. The impact of a
failure of readiness by critical suppliers or major customers or both
cannot be estimated with confidence. The effectiveness of contingency plans
to mitigate the effects of any such failures is largely untested;
23
<PAGE> 2
The Company has employed its standard internal procedures to assess
the reasonableness of its estimates of costs, timing and effectiveness of
remediation of Year 2000 readiness issues. While the Company believes such
an approach is adequate, it should be noted that no external or independent
audit or verification of such estimates has been completed nor have
extraordinary means been undertaken to verify their reasonableness;
Even though the Company expects an increased ability to avoid
significant disruptions of its business as a result of its Year 2000
readiness program, management cannot provide an assurance that there will
be no material adverse effects to the financial condition or results of
operations of the Company as a result of Year 2000 issues; and
The Company may not successfully identify all systems and products
that present Year 2000 readiness issues. Even if the Company successfully
identifies all such systems and products, it may not be successful in
remedying the problems presented.
The foregoing list sets forth many, but not all, of the factors that could
impact upon the Company's ability to achieve results described in any
forward-looking statements. Investors are cautioned not to place undue reliance
on such statements that speak only as of the date made. Investors also should
understand that it is not possible to predict or identify all such factors and
that this list should not be considered a complete statement of all potential
risks and uncertainties. Investors should also realize that if underlying
assumptions prove inaccurate or unknown risks or uncertainties materialize,
actual results could vary materially from the Company's projections. The Company
undertakes no obligation to update any forward-looking statements as a result of
future events or developments.
24
